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Abstract: Sympathetic overactivity and parasympathetic withdrawal indicate profound 
dysregulation of autonomic control in patients with congestive heart failure. 
Pyridostigmine binds to the acetylcholinesterase enzyme and inhibits its action on 
acetylcholine. Thus, pyridostigmine may contribute to restoring the balance between the 
sympathetic and parasympathetic arms of the autonomic system in the heart. We 
hypothesized that pyridostigmine increases parasympathetic tone and thus improves 
autonomic balance in the heart. In the first aim, a rodent model of heart rate recovery 
(HRR) was developed to test the hypothesis that subacute pyridostigmine administration 
enhances HRR in rats. Rapid heart rate deceleration after exercise or HRR is associated 
with the activation of parasympathetic tone. Male Sprague-Dawley rats treated with 
pyridostigmine (0.14 mg/ml/day in the drinking water) showed a significant decrease in 
acetylcholinesterase activity in plasma and red blood cells (RBCs) (P<0.001), whereas 
plasma butyrylcholinesterase activity did not significantly change (P=0.99). HRR 
recorded 1 min after the end of exercise was higher in the pyridostigmine-treated group 
as compared with the control group (P=0.002). The parasympathetic tone was higher in 
the pyridostigmine-treated rats as compared with control (P<0.001) indicating that 
pyridostigmine enhanced parasympathetic tone and associated HRR in rats. Under the 
second aim, analytical methods were developed to quantify pyridostigmine and its 
metabolite 3-hydroxy-N-methylpyridinium in human plasma using sensitive hydrophilic 
interaction liquid chromatography–electrospray ionization–tandem mass spectrometry 
assays. Accuracy and precision values for each assay were within the acceptable limits 
described in FDA guidelines. In the final aim of the study, a population-based 
pharmacokinetic model was used to compare two types of structural base models after 
oral pyridostigmine administration for ten weeks. The two-compartment model was 
determined to best fit the pyridostigmine plasma data and parameter estimates for 
pyridostigmine were reported. In conclusion, subacute pyridostigmine administration to 
rats enhanced HRR by increasing cardiac parasympathetic tone, making this rodent 
model an appropriate tool for further testing of the effects of pyridostigmine of 
autonomic tone. A sensitive method was developed to quantify pyridostigmine and its 
metabolite 3-hyroxy-N-methylpyridinium in human plasma. Lastly, a population-based 
pharmacokinetic model estimated the variability in the pharmacokinetic parameters of 
pyridostigmine in heart failure patient population. 
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CHAPTER I 
 
 
INTRODUCTION 
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The prevalence of heart failure has increased over the years, from 4.9 million people in the 
United States suffering from heart failure in 2001 [1] to 5.7 million in 2013 [2], and it continues to be 
one of the leading causes of sudden death in cardiovascular disease patients. Sudden cardiac death is a 
major concern in these patients with an estimated annual incidence ranging from 184,000 to more 
than 400,000 per year [3]. Neuroendocrine dysregulation is considered to be an important determinant 
of mortality and morbidity in patients with congestive heart failure. Sympathetic overactivity 
concurrent with parasympathetic withdrawal indicates profound dysregulation of the autonomic 
control of the heart. Heart failure is treated pharmacologically, with one goal being to decrease 
mortality by improving sympathovagal balance. Several conditions such as coronary artery disease, 
myocardial infarction, abnormal heart valves, diabetes, severe lung disease, obesity, and high blood 
pressure can lead to heart failure [4]. Heart failure occurs due to the irreversible damage caused to the 
heart over time. However, successful treatment strategies can be applied to manage this condition. 
Treatment plans include changes in lifestyle, medications and, if required, devices and surgical 
procedures. These treatment procedures target specific pathophysiological alterations that occur 
during heart failure. For example, one recommended lifestyle change for heart failure patients is to 
decrease sodium intake, so that less water retention occurs in the body, thereby decreasing circulatory 
volume and the resulting load on the heart and vessels. A second common therapeutic goal is the 
administration of beta blockers to counter excessive, chronic sympathetic stimulation of the heart. 
The administration of angiotensin converting enzyme inhibitors reduces blood pressure and 
circulating volume, thus decreasing preload and afterload on the heart. However, current therapeutic 
approaches do not offset the withdrawal of parasympathetic activity that is also an important event in 
heart failure. Acetylcholinesterase inhibitors such as pyridostigmine may contribute in enhancing the 
parasympathetic tone and normalize autonomic balance in heart.  Acetylcholinesterase inhibitors may 
be used to augment parasympathetic neurotransmission by blocking the enzymatic breakdown of 
acetylcholine at cholinergic receptor sites. 
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In this dissertation, we focus on the administration of an indirect parasympathomimetic drug, 
pyridostigmine. Pyridostigmine is a carbamate, short-acting acetylcholinesterase inhibitor approved 
by the FDA for the treatment of myasthenia gravis. We studied the effects of pyridostigmine on heart 
rate recovery in exercising rats. We also determined the pharmacokinetic behavior of pyridostigmine 
in human congestive heart failure patients. Population pharmacokinetic modeling was performed to 
study the pharmacokinetic effects of the drug in a congestive heart failure patient population.  
The overall hypothesis of this dissertation was that pyridostigmine administration improves 
autonomic regulation during congestive heart failure, as predicted by pharmacokinetic parameters and 
their associated covariates. Our objectives were to determine the effects of subacute exposure of 
pyridostigmine on heart rate recovery in rats and to develop a population pharmacokinetic model to 
describe the variability in the pharmacokinetic behavior of pyridostigmine in human congestive heart 
failure patients. 
Heart rate recovery is a measure of reactivation of the parasympathetic nervous system and is 
considered to be an index of cardiovascular fitness in people. Acetylcholinesterase inhibitors, such as 
pyridostigmine, can enhance parasympathetic tone in the heart and possibly HRR in CHF patients. To 
our knowledge, a study validating the use of HRR to assess autonomic tone in rats has not been 
reported previously. We hypothesize that HRR can be used to assess autonomic tone in rats and that 
subacute administration of pyridostigmine in rats will enhance parasympathetic tone and HRR after 
exercise. To test this hypothesis, our objectives were arrived at as follows: 
The validation of pyridostigmine as a modulator of HRR in rats will be useful in future 
studies that will benefit from the availability of a rodent model to assess pharmacological effects on 
parasympathetic tone. To that end, our first objective was: 
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AIM 1: To validate the use of HRR to assess autonomic tone in rats and to determine the 
subacute effects of pyridostigmine on HRR in rats 
In order to examine the disposition of pyridostigmine in heart failure patients, an analytical 
method was required to quantify the levels of pyridostigmine and its metabolite, 3-OH NMP, in 
human plasma. Therefore, our second objective was: 
AIM 2: To quantify the plasma concentrations of pyridostigmine and its metabolite, 3-OH 
NMP, by developing a highly sensitive and specific assay 
The pyridostigmine plasma data generated under the second aim was used to develop a 
population pharmacokinetic model. We hypothesized that population pharmacokinetic modeling 
would explain the variability in the dose-response effect amongst the CHF patient population and 
could be used to estimate pharmacokinetic parameters of pyridostigmine in patients with CH. This led 
us to our third objective: 
AIM 3: To develop a population-based pharmacokinetic model characterizing the 
pharmacokinetic (PK) properties of repeated oral dosing of pyridostigmine in patients with CHF and 
estimate variability in the resulting pharmacokinetic parameters.  
Our overall hypotheses and specific aims to test that hypotheses integrated several diverse 
fields of science, such as pharmacology, exercise physiology, analytical chemistry, and 
pharmacokinetic modeling. By utilizing and integrating the knowledge from these different areas of 
investigation, we were able to develop a heart rate recovery exercise model in rats. Moreover, we 
developed analytical methods to quantify pyridostigmine and its metabolite 3 hydroxy N-methyl 
pyridinium in human plasma. We also developed a population-based pharmacokinetic model of 
pyridostigmine in CHF patients.  
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In this dissertation, the studies were organized into six chapters.  Chapter I introduces the 
topic of the dissertation and presents the specific aims and hypotheses of the study. In chapter II the 
current knowledge and findings, as well as theoretical and methodological contributions to the 
dissertation topic are discussed as ‘Literature Review.' ‘Subacute pyridostigmine exposure increases 
heart rate recovery and cardiac parasympathetic tone in rats’ was presented in chapter III. In chapter 
IV, the analytical methods were described, ‘Use of hydrophilic interaction liquid chromatography–
tandem mass spectrometry for the quantification of pyridostigmine and its metabolite, 3 hydroxy N-
methylpyridinium in human plasma’. In Chapter V, ‘Population pharmacokinetic analysis of 
pyridostigmine in congestive heart failure patients’ is discussed. Finally, in chapter VI, the topic is 
summarized and concluded by presenting the impactful findings of the study. 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
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1. Congestive Heart Failure 
The 2016 Heart Disease and Stroke Statistical Update by the American Heart Association 
(AHA), in conjunction with the Centers for Disease Control and Prevention, the National 
Institutes of Health, and other government agencies [1] reported that in 2013, 1 in 9 death 
certificates in the United States mentioned heart failure. Data from the Framingham Heart Study 
[2] and the Olmsted County Study [3] shows that survival after diagnosis of heart failure has 
improved over time. However, the death rate is still high with approximately 50% of people 
dying within five years after diagnosis with CHF [3]. Data from NHANES 2009 to 2012 in the 
United States show an estimated 5.7 million people of more than 20 years of age have CHF 
(Figure 1). Projections show that the prevalence of CHF will increase from 2012 to 2030 by 46% 
[4] (Figure 2). According to the census from 2005, in the US, approximately 5 million cases of 
CHF per year are reported. Elderly patients above the age of 65 present the majority of cases of 
CHF [5]. 
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Figure 1: Prevalence of heart failure by sex and age as reported by National health and 
nutritional examination survey: 2009-2012. Sources: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute. This figure is adapted from 2015 Heart Disease and 
Stroke Statistical Update by American Heart Association (AHA) [6]. 
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Figure 2: Projected prevalence of HF from 2012 to 2030 is shown for men and women in the 
United States. The prevalence of HF remains highest among men throughout the period, although 
it increases among both groups over time. HF indicates heart failure. This figure is adapted from a 
manuscript by Paul A. Heidenreich, entitled ‘Forecasting the Impact of Heart Failure in the 
United States: A Policy Statement from the American Heart Association’ [4]. 
 
Congestive heart failure (CHF) can be defined as “the pathophysiologic state in which, 
because of an abnormality of cardiac function, the heart fails to pump the blood at a rate 
commensurate with the requirements of the metabolizing tissues, or else does so only with an 
elevated filling pressure” [7]. Heart failure is often a long-term (chronic) condition, but it may 
also occur suddenly.  
There are two major categories of heart failure: systolic and diastolic heart failure. In 
systolic heart failure, the heart muscle cannot pump the blood effectively, whereas, in diastolic 
heart failure, the heart muscle becomes stiff and does not relax sufficiently to fill with blood, 
resulting in a decreased ejection volume.  
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Abnormalities such as pressure and volume overload, loss of cardiac muscle, excessive 
peripheral demands, etc. may cause CHF [8]. In developed countries, ventricular dysfunction is 
more prevalent and occurs mainly due to myocardial infarction and hypertension. Other causes of 
heart failure include degenerative valve disease, idiopathic cardiomyopathy, and alcoholic 
cardiomyopathy [9]. 
Clinical signs and symptoms 
Symptoms of CHF can be of slow or sudden onset. Initially, symptoms may occur only 
during maximum activity. Eventually, patients may notice breathing problems even when resting. 
Common symptoms of CHF are cough, tiredness, weakness, fainting, loss of appetite, the urge to 
urinate during the night, irregular pulse, short breath, bloating, swelling of extremities and 
internal organs and weight gain [10]. 
Pathophysiology 
Disturbance in myocardial contraction leads to decreased cardiac output. To improve the 
cardiac output, several compensatory mechanisms including Frank-Starling relationship, 
sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) activation, 
secretion of arginine vasopressin, and the development of myocardial hypertrophy are utilized by 
the cardiovascular system. These mechanisms are effective in preserving cardiac output, 
supporting systemic blood pressure, and ensuring adequate cerebral perfusion in the short term. 
However, the persistence of such pathophysiologic alterations has long-term deleterious effects 
on cardiac function [11]. In the usual form of heart failure, contractility of the heart muscle is 
decreased which produces a reduction in cardiac output, and then the heart becomes unable to 
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meet the peripheral demands of the body. Disturbances in cardiac output alter the following four 
primary determinants of left ventricular (LV) performance:  
(1) Decrease in cardiac muscle contractility.  
(2) Increase in preload or left atrial filling pressure causes congestion and dyspnea.  
(3) The increase in afterload or systemic vascular resistance causes hypertensive conditions.  
(4) The increase in heart rate as part of the compensatory mechanism produces an increase in 
sympathetic tone and circulating catecholamines [8]. 
Neurohormonal activation 
CHF associates with alterations in the nervous and endocrine systems. Under normal 
physiological conditions, these neurohormonal compensatory mechanisms provide valuable 
support for the heart. However, in CHF conditions, they play a role in the development and 
subsequent progression of the disease.  These neurohormonal alterations include stimulation of 
the RAAS, increase in the activity of the sympathetic nervous system, release of natriuretic 
peptides, increase in the levels of antidiuretic hormone vasopressin, the release of endothelin, and 
withdrawal of cardiac parasympathetic activity (Figure 3) [12]. In our research, we focus on 
pharmacological management of the changes that occur in the parasympathetic control of the 
heart during CHF.  
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Figure 3: Neurohormonal alterations occurring during CHF. This figure was adapted from a 
published article by Floras, J.S., ‘Sympathetic nervous system activation in human heart failure: 
clinical implications of an updated model.’ J Am Coll Cardiol, 2009. Ach = acetylcholine; CNS = 
central nervous system; E = epinephrine [18, 19]. 
 
Management 
The therapy of CHF is mostly directed at restoring normal cardiopulmonary physiology 
and reducing the hyper-adrenergic state. Dietary management of CHF includes less salt intake to 
control fluid retention [13, 14]. Most patients also need diuretic therapy. Vasodilators like nitrates 
have also been used to reduce the vasoconstriction caused by the over-activation of the 
sympathetic nervous system [15]. These management approaches improve preload. Decreasing 
the activity of the RAAS by administering angiotensin-converting-enzyme (ACE) inhibitors 
reduces afterload. Another approach in the management of heart failure is to improve the 
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contractility of cardiac muscle with a positive inotrope, like digoxin, and controlling the activity 
of beta-receptors with beta blockers like atenolol and propranolol. Phosphodiesterase inhibitors 
also increase contractility of the heart and cause peripheral vasodilation [11]. In some cases, life-
supporting devices such as a defibrillator or pacemaker may be implanted.  
Recent efforts to treat CHF have focused on specific treatment modalities, such as spinal 
cord stimulation, electrical vagus nerve stimulation [16], activation of baroreceptors, and 
denervation renal sympathetic nerve [17]. One such emerging treatment modality is the 
reactivation of the parasympathetic nervous control of the heart, which is withdrawn in CHF. 
2. Pyridostigmine Bromide 
Chemical Structure and Mechanism of Action 
Pyridostigmine (PYR) is a positively charged quaternary ammonium carbamate 
compound (Figure 4).  PYR carbamylates the active site serine residue of acetylcholinesterase 
(AChE) which prevents acetylcholine (ACh) from binding to these same sites and being 
hydrolyzed by the enzyme. AChE inhibition thus leads to a buildup of Ach in the neuromuscular 
junction (NMJ) or cholinergic synapse, resulting in an increased/prolonged action of ACh at 
cholinergic receptors. Pyridostigmine also has additional actions, such as direct binding and 
stimulation of ACh receptors [20]. Administration of pyridostigmine (25 mg/kg/day) for a 
prolonged period can downregulate acetylcholine receptors and lead to neuromuscular 
dysfunction, with or without receptor changes [21]. 
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Figure 4: Structure of pyridostigmine bromide (This figure was adapted from sigmaldrich.com, 
http://www.sigmaaldrich.com/catalog/substance/pyridostigminebromide2611210126811?lang=en
&region=US) 
 
Effects of pyridostigmine occur via the action of ACh at the nicotinic and muscarinic 
cholinergic receptors in the skeletal NMJ, autonomic end-organs of the sympathetic and 
parasympathetic nervous systems, autonomic ganglia, and the central nervous system. Effects of 
enhanced nicotinic receptor stimulation can include changes in muscle tone, altered cognitive 
functions, modulation of reward, arousal and motor control, and analgesia [22].  Similarly, the 
action of ACh at muscarinic receptors in smooth muscles, glands, and the heart is affected by 
pyridostigmine. These muscarinic effects can include spasm of smooth muscles, increased 
glandular secretions, and slow of the heart rate [23]. ACh activity is mostly regulated by the 
enzyme acetylcholinesterase (also called "red blood cell cholinesterase" or "RBC cholinesterase" 
or "true cholinesterase" and abbreviated as "AChE"). ACh binds and is rapidly inactivated by 
AChE in cholinergic synapses. This hydrolytic breakdown of ACh prevents inappropriate, 
excessive signaling at the postsynaptic cholinergic terminal. Butyrylcholinesterase (also called 
"plasma cholinesterase" or "pseudocholinesterase," and abbreviated as "BChE") plays a less 
critical role. BChE is made in the liver and secreted into the circulation, but is found in most 
tissues throughout the body [24].  
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ADME 
Oral bioavailability of pyridostigmine was reported to be 7.6 ± 2.4%, indicating that 
pyridostigmine is poorly absorbed from the GI tract [25]. The charged quaternary ammonium 
leads to high water solubility, and it is mostly absorbed in the duodenum, but overall it is poorly 
absorbed from the gastrointestinal tract [26]. PYR is rapidly excreted by glomerular filtration and 
active tubular secretion by the kidneys. In a study performed in healthy controls and myasthenia 
gravis patients, peak pyridostigmine concentrations were reached between 1 ½ to 2 hr after oral 
administration of a 60 mg dose and the time of peak concentration was similar between the 
groups [27].  
In healthy subjects in which 2.5 mg of pyridostigmine was administered IV, the plasma 
elimination half-life was 1.52 hr, the volume of distribution (Vd) was 1.43 L/kg, and plasma 
clearance was 0.65 L/kg*hr. The pharmacokinetic parameters obtained after oral administration 
of 120 mg tablet of pyridostigmine were slightly different from that reported after IV dose; 
elimination half-life was 1.78 ± 0.24 hr, the Vd was 1.64 ± 0.29 L/kg, and the plasma clearance 
was 0.66 ± 0.22 L/kg*hr. A greater than the seven-fold difference in steady state pyridostigmine 
plasma concentrations was found between myasthenia gravis patients taking similar daily doses. 
However, the pharmacokinetic data from the healthy subjects was not able to explain these higher 
differences in the steady state pyridostigmine plasma concentrations [25].  
In humans and other animal species, such as dogs and rats, pyridostigmine is mainly 
metabolized to 3-hydroxy-N-methylpyridinium (3-OH NMP) (Figure 5), which is excreted in 
urine along with the unchanged drug [29]. This metabolite does not contribute to antagonism of 
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neuromuscular blockade in dogs [30].  The drug and the metabolite are not bound to protein. Both 
blood cholinesterases and microsomal enzymes in liver play an important role in the metabolism 
of pyridostigmine [31]. In another study, the elimination of unchanged drug in rats remained 
constant for different levels of doses when administered via the portal vein. However, the 
percentage of the metabolite eliminated decreased with the increase in the level of doses 
suggesting a zero-order elimination for pyridostigmine and a dose-dependent process (first order 
kinetics) for the elimination of 3-OH NMP [29].  
Figure 5: Metabolic pathway of pyridostigmine bromide. This figure was adapted from a review 
article by Zhao B et al., 2006, ‘Determination of pyridostigmine bromide and its metabolites in 
biological samples’ [28].  
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Indications 
Pyridostigmine bromide is one of the main drugs for the treatment of myasthenia gravis. 
[32]. In military personnel, pyridostigmine is used as a prophylactic agent against the nerve 
agents such as sarin and soman, which lead to very long-term inhibition of AChE [34]. The 
protective property of pyridostigmine is due to its ability to shield the active site of AChE for a 
short time, to prevent the much longer inhibition elicited by the nerve agents. Pyridostigmine 
may, therefore, be useful as a pre-treatment to minimize the effect of organophosphate nerve 
agent intoxication, especially if used in conjunction with the standard antidotes, atropine and 
pralidoxime chloride (2-PAM) [35, 36]. The quaternary nature of pyridostigmine impedes its 
passage across the blood–brain barrier to limit central nervous system effects [37]. 
3. Reactivation of parasympathetic function 
Pyridostigmine is an indirect parasympathomimetic drug which enhances 
parasympathetic tone by covalently binding to AChE, thus inhibiting the hydrolysis of ACh 
molecules in the synapse. This concept is supported by many human and animal studies 
indicating that pyridostigmine enhances parasympathetic tone [38-43]. Recently, Lataro et al. 
administered pyridostigmine in the drinking water (four weeks at 0.14 mg/mL) to rats with 
experimental heart failure and reported that PYR enhanced cardiac vagal tone and reduced 
sympathetic tone [42]. Similarly, Sabino et al. administered pyridostigmine to heart failure rats at 
this same dose rate. Pyridostigmine was efficient at preventing the attenuation of baroreflex 
sensitivity, which is a typical outcome of heart failure. Besides, pyridostigmine treatment avoided 
changes in iHR (intrinsic heart rate) and autonomic cardiovascular control, as examined by 
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arterial pressure variability and cardiac parasympathetic tone [44]. The same group also found 
that pyridostigmine prevented increased peripheral chemoreflex sensitivity and partially blunted 
central chemoreflex sensitivity, but did not affect basal pulmonary ventilation in HF rats [45]. 
It has been previously reported that pyridostigmine improved tolerance to peak exercise 
and inhibited the chronotropic response to submaximal exercise in human patients with exercise-
induced angina [46]. These results suggest that pyridostigmine can provide protection against 
exercise-induced myocardial ischemia. In another study in human coronary artery disease 
patients, pyridostigmine reduced QTc interval [39]. These results indicate that oral 
pyridostigmine produces tonic cardiac cholinergic stimulation while exerting no effect on its 
reflex changes. Further studies are needed to understand the potential role of pyridostigmine on 
the prognosis of patients with acute myocardial infarction [47]. 
4. Heart rate recovery 
Cardiac autonomic function can be assessed in healthy subjects or CHF patients by using 
various tools, including the chronotropic response of the heart to physiological stress and 
pharmacological blockade [48,49], heart rate variability (HRV) [50,51], quantification of 
baroreflex sensitivity [52], plasma or coronary sinus catecholamine levels [53], HR turbulence 
[53], and others. Heart rate recovery (HRR) is the rate at which heart rate decelerates after 
moderate to heavy exercise and is dependent on the relative changes between the parasympathetic 
and sympathetic nervous activities of the autonomic nervous system [54]. The analysis of beat by 
beat heart rate decay after exercise may have the potential to deduce an indicator of vagally 
mediated heart rate recovery, providing fine time resolution [55]. 
 20 
 
Parasympathetic activation and HRR  
Intrinsic activity of the sinus node, in conjunction with the parasympathetic and 
sympathetic system, determines the heart rate. At the beginning of the exercise, the increase in 
heart rate is mediated by the withdrawal of the parasympathetic system. Activation of 
sympathetic system is responsible for maintaining exercise tachycardia with the vigorous levels 
of exercise. When exercise is stopped, reactivation of parasympathetic system and withdrawal of 
sympathetic system contributes to the recovery of heart rate. However, the relative contribution of 
these components of the autonomic system during recovery phase was not completely elucidated. 
Savin et al. postulated that in healthy subject sympathetic withdrawal contributes more to 
the HRR soon after peak exercise, while parasympathetic reactivation plays a greater role later in 
recovery [56]. In a subsequent similar study, Imai et al. found that HRR was accelerated in 
trained athletes but blunted in patients with heart failure [55]. They concluded that immediately 
after exercise the decrease in heart rate is primarily due to parasympathetic reactivation. The 
increase in plasma norepinephrine levels at about 1 minute after high-level of exercise indicates 
that sympathetic activity remains high during the early recovery phases [57]. A higher level of 
sympathetic activity during early phases of recovery implies that the fall in heart rate that occurs 
during this period is highly dependent on parasympathetic reactivation.  
Savin et al. attempted to assess the contribution of the autonomic nervous system to heart 
rate recovery following exertion by parasympathetic blockade with atropine sulfate, sympathetic 
blockade with propranolol hydrochloride, double blockade with both drugs, all compared to 
responses with no drug administration [56]. Results suggested that heart rate recovery occurs in 
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an exponential manner. In the same study, the authors suggested that deceleration of heart rate 
could be an intrinsic property of the heart because it occurred under each experimental condition. 
These authors proposed that the contribution of sympathetic withdrawal to heart rate recovery 
soon after peak exercise is higher and parasympathetic activation plays a major role later in 
recovery [56].  
However, the above results were contradicted by Perini et al. when he studied the time 
course of heart rate and venous blood epinephrine concentration as an expression of sympathetic 
nervous system activity during recovery from periodic exercise cycles [58]. His results suggested 
that in the first minute of recovery, independent of exercise intensity, the recovery was mainly 
due to the restoration of vagal tone. The further decrease in heart rate was attributed to the return 
of sympathetic nervous activity to pre-exercise level [58]. 
Congestive heart failure and HRR  
On comparing the heart rate recovery between two different physiological groups, it was 
found that HRR is blunted in chronic heart failure patients and accelerated in trained athletes. 
This difference could exist because the parasympathetic activity is altered in CHF patients [48, 
59].  
Heart rate recovery as a predictor of mortality  
Delayed heart rate recovery can be an important prognostic marker in patients with CHF. 
Cole et al. performed a cohort study in patients without evidence of cardiovascular disease [60]. 
HRR, measured one minute after termination of exercise, of 12 bpm or less after peak exercise 
was defined as abnormal (26% of patients in the study) and a delayed decrease in HR after graded 
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exercise was regarded as a powerful predictor of overall mortality [61]. Nishime EO et al. 
recommended HRR as a better technique than treadmill exercise scoring for routine incorporation 
into exercise test interpretation [62]. In the cohort study performed by Watanabe J, an abnormal 
HRR was defined as ≤18 bpm [63]. An abnormal heart rate recovery was able to predict mortality 
whether or not left ventricular systolic dysfunction was present [63]. Dimkpa U has also 
discussed the physiological implications and clinical and practical applications of HRR [64]. 
Dimkpa U associated HRR to maximum oxygen uptake, endurance capacity and central 
hemodynamic variables like resting HR and resting blood pressure [64]. 
5. Tandem mass spectrometry 
Mass spectrometry generates ions from either inorganic or organic compounds by a 
suitable method. Then the mass spectrometer separates these ions according to their mass-to-
charge ratio (m/z) to identify and quantify their abundance (Figure 6). Different methods of 
ionization can be used such as thermal, by electric fields, or by impacting energetic electrons, 
ions, or photons on the analytes. Ion separation is effected by dynamic electric or magnetic fields 
[65]. There are different types of mass analyzers available such as time of flight (TOF), 
quadruple, ion traps, and Fourier transform (FT) resonance detectors. The ion sources can be 
matrix-assisted laser desorption/ionization (MALDI), electrospray, and plasma fields (ICP, 
APCI). 
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Figure 6: Components of a mass spectrometer. This figure was adapted from the webpage of 
Premier Biosoft (http://www.premierbiosoft.com/tech_notes/mass-spectrometry.html). 
 
Principle of tandem mass spectrometry 
As described above, a mass spectrometer works on the principle of ionization and 
detection. However, in a tandem mass spectrometer, there are two mass spectrometers linked end 
to end. In the first mass spectrometer, the parent ion is selected, and then it is fragmented into 
several daughter ions by bombardment of electrons on the molecules in the ionization chamber. 
These daughter ions can then be detected or measured in the second mass spectrometer.  
Uses and advantages 
Liquid chromatography-tandem mass spectrometry (LC/MS/MS) provides superior 
sensitivity and selectivity of analytes. The liquid chromatography, in most cases, eliminates the 
need for derivatization. It is efficient in separating and identifying similar compounds.  When 
operating in multiple reaction monitoring (MRM) mode, quantification of low levels of 
compounds in biological matrices becomes feasible. 
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Analytical methods available in literature 
Several analytical methods for the quantification of pyridostigmine have been developed 
and published. There are different analytical techniques involved in those methods such as 
radioactive [28, 66, 67], chromatographic, capillary electrophoresis [68, 69] techniques, and other 
biological techniques e.g. RIA [70].  Assays reported in the published materials for quantifying 
pyridostigmine and 3-OH NMP are listed in Table 1. There is only one mass spectrometry (MS) 
method published so far for the quantitation of pyridostigmine [71]. However, this MS method is 
developed to analyze pyridostigmine in guinea pig plasma. The lower limit of quantitation 
(LLOQ) of the method is 0.1 ng/mL. To our knowledge, there is no MS method for the 
determination of the metabolite 3-OH NMP. 
Table 1: Reported procedures for the determination of pyridostigmine and its metabolite 
(Adapted from Zhao B et al., 2006 [28]) 
Compound Sample Extraction 
method 
Stationary 
Phase 
Detection 
Mode 
Validation 
Data 
Refs. 
PYR and 
3-OH 
NMP 
Plasma& 
urine 
(rat) 
SPE µBondapa
k C18 
 
UV, 280 LIN: 100 – 1000ng/ml 
LOD: 50ng/ml (for both) 
[72] 
PYR Plasma 
(guinea 
pig) 
LLE SCX 
poly(2-
sulfoethyl 
aspartami
de) 
column  
MS, m/z 1
80.8 → 
124.0 
LIN: 0.1 – 50ng/ml 
LOQ: 0.1ng/ml 
[71] 
PYR Plasma 
(human) 
SPE Axiom 
Silica 
column  
UV, 208 LIN: 1.53 – 76.3ng/ml 
LOQ: 1.53ng/ml 
[36] 
PYR and 
3-OH 
NMP 
Serum 
(human) 
LLE LiChrosor
b RP-8 
 
UV, 214 LIN: 0 – 1000ng/ml 
(PYR) 
LOQ: 5ng/ml (PYR) 
[73] 
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PYR 
  
Plasma 
(human) 
SPE µBondapa
k C18 
 
UV. 254 LOD: 1ng/ml [32] 
PYR and 
3-OH 
NMP 
Plasma 
& urine 
(human 
& rat) 
SPE µBondapa
k C18 
 
UV, 270 LIN: 49 – 4900ng/ml 
(PYR) 
 
[74] 
PYR Plasma 
(human) 
SPE CPS 
Hypersil 
NC-04 
column  
UV, 272 LIN: 5 – 200ng/ml 
LOD: 1ng/ml 
[75] 
PYR Plasma 
(Human) 
LLE µBondapa
k C18 
 
UV, 269 LIN: 20.8 – 104.1ng/m 
 
[76] 
PYR Plasma 
(human) 
SPE Radial-
Pak CN 
column  
UV, 270 LIN: 10 – 200ng/g 
LOD: 2ng/g 
[77] 
PYR Plasma 
(human) 
SPE Altex 
Ultra-
sphere 
Octyl 
column 
  
UV, 208 LIN: 0 – 68.3ng/ml 
LOD: 1.37ng/ml 
  
[78] 
PYR and 
3-OH 
NMP 
Plasma& 
urine 
(rat) 
SPE µBondapa
k C18 
 
UV, 280 LIN: 100 – 1000ng/ml 
LOD: 50ng/ml (for both) 
[79] 
PYR Plasma 
(human) 
SPE Cation 
exchange 
column 
UV LIN: 5 – 100ng/ml 
LOQ: 5ng/ml 
[80] 
 
6. Population pharmacokinetic modeling 
Modeling plays a critical role during drug development. It has been very well said by 
Atkinson and Lalonde that “dose selection and dose regimen design are essential for converting 
drugs from poisons to therapeutically useful agents [81].” Modeling and simulation serve as 
important tools during drug development and its usage.  In general, pharmacokinetic and 
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pharmacodynamic modeling is useful in predicting the time course of exposure and response 
Moreover, population modeling, in particular, is useful for quantitating and explaining variability 
in drug exposure and response.  
Population modeling was first introduced in 1972 by Sheiner et al. [82]. The earlier 
methods such as naïve pooled average and standard two-stage have some problems which may 
lead to biased parameter estimates. These problems become worse when samples in the data are 
missing, sampling is sparse, or poor dosing compliance exists [83]. The population approach 
developed by Sheiner et al. addressed these problems. Moreover, the population modeling 
approach allows pooling of sparse data from many different sources to estimate mean population 
parameters, between subject variability (BSV). Population approach also helps in estimating the 
covariate effects that quantitate and explain variability in drug effect and exposure. Measuring 
parameter precision was also feasible with this approach by the generation of standard errors. 
The components of population model  
A population model is comprised of three main components: 
a.    The structural model consists of algebraic or differential equations which describe the time 
course of effect and exposure of the drug. 
b.    The statistical model describes the variability (such as interindividual, interoccasion) or 
random effects variability in the population.  
c.    The covariate model describes the influence of factors on the variability and parameter 
estimates of the population.   
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In population modeling approach, all data from all individuals are analyzed 
simultaneously using a nonlinear mixed effects model. The term “nonlinear” indicates that 
dependent variable (e.g., concentration) is nonlinearly related to the model parameters and 
independent variables. Parameters that do not vary across individuals are called “fixed effects,” 
and the parameters that vary across individuals are called “random effects” When both, fixed and 
random effects parameters are estimated simultaneously in a model, it indicates a mixed effect 
model. [84]. 
Population model development 
Data consideration   
While developing a population model, several different considerations are involved 
including database formation, selection of software and estimation method, comparing models, 
structural model development, statistical model selection, covariate model building and finally 
performing model evaluations. All these steps when performed aid efficiently in an accurate, 
appropriate and reliable model.  
The first step of generating database for population analysis is one of the most critical 
and time-consuming part of the evaluation [85]. Data need to be thoroughly scrutinized for 
accuracy. Data can be graphed initially to identify potential errors and outlier.  Early diagnostic 
analysis can also be performed to understand the data and its content. The right section of the 
software and estimation method is very important in modeling. Many population modeling 
software packages are available and so choosing a package requires careful consideration 
including familiarity with the software package, available online support for the package, cost, 
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and how well-establishes the package is. The software packages available today are mostly based 
on the maximum likelihood approach where parameter estimations are performed by minimizing 
an objective function value (OFV) [85]. The OFV is the negative twice the log of the likelihood, 
and this single number tells us how closely the model predictions match to the observed data.  
Considering the influence of fixed and random effects on the model, an approximate marginal 
likelihood is calculated by employing different estimation methods such as FO, FOCE, 
LAPLACE and SAEM [86]. All estimation methods have their advantages and disadvantages 
which are mostly related to the speed, robustness, precision and stability [87, 88].  
While developing population models, different approaches are tried, and the resulting 
models are compared. As mentioned above, the minimum OFV is important for comparing and 
ranking models. However, Akaike information criterion (AIC) and Bayesian information criterion 
(BIC) can also be used to compare models in case of increased complexity regarding a number of 
parameters and number of data observations.  
AIC= OFV +2*np 
BIC= OFV+ np * Ln (N) 
Where, np is the total number of parameters in the model and N is the number of data 
observations.  
The careful evaluation of structural model is important because it has implications in 
selecting a covariate model [89]. The structural model describes the kinetics of the drug after IV 
(systemic model) and extravascular (absorption model) administration.  
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 Similar to the structural base model, an appropriate statistical model is also important for 
the evaluations of covariates. The statistical model helps in describing the variabilities such as 
between subject and random variability in the population. Statistical models also have 
implications in determining the amount of remaining unexplained variability in the data and 
performing simulations [85]. 
Identification of covariates that explain the variability in the pharmacokinetic response of 
the drug in population is important. Building a covariate model is a stepwise approach in which 
the potentially important covariates are selected first, and then they are screened based on 
regression, correlation, etc. Covariates can also be evaluated graphically for visible and 
significant relationships. Thorough initial evaluation to limit the number of important covariates 
in the model can considerably reduce runtime. In the last step of covariate model development, all 
relevant covariates which meet inclusion criteria during screening are included in the model. 
Significance levels are pre-specified, and the covariates are dropped one after the other and 
changes in the goodness-of-fit of the model are tested. This process is continued until the simplest 
possible model is left by testing and reducing not significant covariates.  
Model evaluation is the final step of population analysis. In initial stages, models are 
compared based on their OFV. However, in later stages, simulations are performed, and methods 
such as the visual predictive check (VPC) may be more useful for effective model evaluation. 
Some important evaluation methods are listed below: 
a. Graphical evaluation: Graphical representation of residuals to evaluate model fitting is 
fundamental in pharmacometrics.  
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b. Parameters, SE and confidence intervals: Assessment of precision of the parameter estimates 
and their plausibility is an important method of model evaluation.   
c. Visual predictive checks: New database is simulated using the final model and prediction 
intervals are constructed from simulated concentration-time profiles and compared with 
observed data. 
There are two population studies performed on pyridostigmine. The first study, by 
Marino MT et al. [36] was conducted on healthy volunteers to assess the use of pyridostigmine 
bromide for prophylaxis against nerve agent poisoning. In this multiple doses, placebo-controlled 
and randomized double-blind study, pyridostigmine was administered orally at a dose rate of one 
30 mg tablet every eight hours for 21 days. Samples were collected once before and at multiple 
later time points until 8 hours after the first dose. During the 21 day treatment period, samples 
were collected once every three days. After the last dose had been administered, samples were 
collect until 72 hours afterward. These samples were analyzed for plasma concentrations of 
pyridostigmine and red blood cell cholinesterase levels. The red blood cell cholinesterase activity 
had shown correlation with survival in nerve agent exposure in some animal models and 
therefore, RBC ChE activity was selected as the pharmacodynamic endpoint [90]. 
The methods adopted in this article report that standard two-stage procedure was 
followed using NONMEM IV version 2.1. A two-compartment model with first-order absorption 
(with lag time) and elimination was used to fit the pyridostigmine plasma concentrations.  
The results of this study suggested that the PK parameters of pyridostigmine are 
dependent on both gender and weight. The pharmacodynamic (PD) effects were directly 
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proportional to the plasma concentration and returned to near baseline conditions within 8 hours 
after pyridostigmine administration.  
In another retrospective pop PKPD study in Chinese subjects [91], pyridostigmine was 
administered at a similar 30 mg dose every 8 hours for three days, and the plasma concentrations 
of pyridostigmine and RBC AChE activity were determined at various time points. Unlike the 
previous study by Marino et al., a one-compartmental open model with first order absorption 
(with a lag term) and elimination fitted the PK data best. First-order conditional estimate (FOCE) 
with interaction and inhibitory Emax model within NONMEM were used to develop the PK and 
PD model respectively.  
Unlike the previous study, the tested covariates were not correlated with any of the model 
parameters. Simulations performed by the researchers suggested a dose of 30 mg every 6 hours to 
maintain a steady state trough percentage above 10% in healthy Chinese males. 
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CHAPTER III 
 
 
SUBACUTE PYRIDOSTIGMINE EXPOSURE INCREASES HEART RATE RECOVERY 
AND CARDIAC PARASYMPATHETIC TONE IN RATS 
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Abstract 
The rapid deceleration of heart rate after strenuous exercise, heart rate recovery (HRR), is 
an indicator of parasympathetic tone. A reduction in parasympathetic tone occurs in patients with 
congestive heart failure resulting in delayed HRR. Acetylcholinesterase inhibitors, such as 
pyridostigmine, can enhance parasympathetic tone by increasing cholinergic input to the heart. 
The objective of this study was to develop a rodent model of HRR to test the hypothesis that 
subacute pyridostigmine administration decreases cholinesterase activity and enhances HRR in 
rats. Ten days after implantation of radiotelemetry transmitters, male Sprague-Dawley rats were 
randomized to control (CTL) or treated (PYR) (0.14 mg/ml pyridostigmine in the drinking water, 
29 days) groups. Rats were exercised on a treadmill to record HRR, and blood samples were 
collected on days 0, 7, 14, and 28 of pyridostigmine administration. Total cholinesterase and 
acetylcholinesterase (AChE) activity in plasma was decreased by 32-43% and 57-80%, 
respectively, in PYR rats on days 7-28, while plasma butyrylcholinesterase activity did not 
significantly change. AChE activity in RBCs was markedly reduced by 64-66%. HRR recorded 1 
min after exercise was higher in the PYR group on days 7, 14 and 28, and on day 7 with HRR 
recorded at 3 and 5 min. The autonomic tone was evaluated pharmacologically using sequential 
administration of muscarinic (atropine) and adrenergic (propranolol) blockers. The 
parasympathetic tone was increased in PYR rats, but no significant difference was noted in the 
CTL group. These data support the study hypothesis that subacute pyridostigmine administration 
enhances HRR by increasing cardiac parasympathetic tone. 
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Introduction 
The autonomic nervous system is important in controlling cardiovascular functions. 
Neuroendocrine dysregulation, indicated by sympathetic over-activity and parasympathetic 
withdrawal, is an important determinant of mortality and morbidity in patients with congestive 
heart failure (CHF) (1). The cardiac autonomic function can be assessed in healthy subjects or 
CHF patients by using various tools. These assessment methods include chronotropic response of 
the heart to both physiological stress and pharmacological blockade (2, 3), heart rate variability 
(HRV) analysis (4, 5), quantification of baroreflex sensitivity (6), plasma or coronary sinus 
catecholamine levels (7), HR turbulence (7), and others. Heart rate can be recorded noninvasively 
and inexpensively with the aid of commercially-available and automated equipment. Heart rate 
recovery (HRR) and HRV can also be easily derived (8), and so more focus has been directed to 
analysis of HRR and HRV. Recently, HRR, preferably measured after submaximal exercise to 
avoid possible sympathetic activity interference (9, 10), has been used to approximate 
parasympathetic tone in human subjects (11). HRR is an index of cardiac parasympathetic tone 
and has clinical utility in predicting cardiovascular fitness, disease prognosis, and mortality in 
heart failure patients (12-16).  
Some of the earliest clinical evaluations of heart rate recovery were performed by Perini 
and Imai and coworkers (9, 10). They observed that the early (within 1 min) recovery of heart 
rate after exercise is mediated by parasympathetic reactivation. Later, Pierpont and coworkers 
quantitatively linked HRR to parasympathetic function in healthy volunteers (17, 18). Shelter and 
Watanabe validated the use of HRR as a predictor of mortality in human subjects (13, 19). 
However, there are very few studies which support the use of HRR to evaluate parasympathetic 
tone in rats. Barnard (1974) discussed the effect of training rats to near maximal heart rates and 
changes in HRR during this period but did not correlate these with changes in cardiac 
parasympathetic tone (20).  
 46 
 
Acetylcholinesterase inhibitors, such as pyridostigmine, can increase parasympathetic 
activity by increasing acetylcholine levels at the vagal cholinergic nerve terminals innervating 
cardiac tissue. Previous studies by Androne and co-workers demonstrated that short-term 
pyridostigmine treatment augmented parasympathetic tone and increased HRR in stable CHF 
patients (21). Similarly, Serra et al. found that the chronotropic response to exercise in heart 
failure patients was reduced by pyridostigmine (22). The objective of our study was to develop a 
rodent exercise model of HRR and to test our hypothesis that subacute administration of 
pyridostigmine enhances HRR after submaximal exercise in normal rats by increasing cardiac 
parasympathetic tone. 
Material and methods 
Optimization of experimental methods 
A pilot study was performed to estimate the number of animals needed per group. From 
the pilot study, it was determined that intraabdominal implantation of the radiotelemetry 
transmitter device with an intradermal suture pattern led to a faster recovery as compared to the 
subcutaneous implantation and simple interrupted sutures. The exercise performance of rats with 
increasing treadmill speed was tested and accordingly, the highest running speed was set at 20 
meters per minute (m/min). From the pilot study (data not shown), a sample size of eight rats per 
treatment group was calculated to be sufficient to detect a difference of 44 beats/min in HRR at 1 
minute between each treatment group with a power of 80% and an alpha of 0.05. As per the 
findings of the pilot study, we designed the following experiment.  
Experimental animals 
Sixteen male, 8-9 week old, Sprague-Dawley rats weighing 275-300 g at onset were 
purchased from Charles River (Wilmington, MA). The rats were housed individually and 
maintained on a 12-hour light-dark cycle in an Association for Assessment and Accreditation of 
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Laboratory Animal Care International (AAALAC International)-accredited facility. Rats were 
given ad libitum access to water and standard laboratory rodent chow. All animal experiment 
protocols were reviewed and approved by the Oklahoma State University Institutional Animal 
Care and Use Committee. 
Surgical implantation of radiotelemetry device 
After one week of acclimatization, the CTA-F40 small animal radiotelemetry transmitter 
device from Data Sciences International (DSI, St. Paul, MN) was surgically implanted under 
isoflurane general inhalation anesthesia. The surgical protocol followed was adapted by the 
recommendations of DSI (ETA, CTA, EA, or CA Device Surgical Manual).  A single dose of 
morphine (5 mg/kg, IM) was administered before surgery. Meloxicam (2 mg/kg, bid, SQ) was 
administered to all rats for three days after surgery and enrofloxacin (Baytril®, 5 mg/kg, bid, SQ) 
for five days after the surgery. The rats recovered uneventfully.  
Measuring heart rate (ECG) by telemetry  
Data were collected using a TA11CTA-F40 implant, PhysioTel Receiver Model RPC-1, 
and DataQuest ART (Advanced Research Technology) Version 4.0 software (DSI). This allowed 
the continuous collection of electrocardiograms from conscious rats.  
Exercise training and exercise protocol 
After recovering from surgery, each rat was trained for three days to run on the treadmill. 
During this training period, rats were allowed to run continuously under increasing speeds to 
determine their submaximal level of exercising.  Rats initially ran at a speed of 5 m/min at a 10% 
grade for 10 min. After that, the treadmill was held at a constant grade while the speed was 
increased by 5 m/min every 5 min until the rat was unable or unwilling to maintain pace with the 
treadmill belt (modified from [3]). The heart rate at this stage was considered as their maximum 
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exercise heart rate, and the speed was recorded. The submaximal exercise level was considered as 
80% of the maximal HR and the speed, 20 m/min, at which it was achieved, was noted for future 
experiments. According to the final exercise protocol, the treadmill was inclined at 10% grade 
and the speed of treadmill was increased by 5 m/min every 3 min until reaching 20 m/min. At the 
20 m/min speed, the rats were run for 6 min, after which the treadmill was stopped and the rats 
were allowed to rest on the treadmill for 5 min.  
Pyridostigmine treatment  
After recovery from the surgery, rats were randomly divided into pyridostigmine treated 
(PYR) and control (CTL) groups (n=8 per group). The PYR group received 0.14 mg/mL [4-6] of 
pyridostigmine dissolved in drinking water, whereas the CTL rats received only water for 29 
days. Stability of pyridostigmine in water was confirmed by mass spectrometry (MS). 
Pyridostigmine in water was found to be stable in both ambient and cold (4° C.) temperatures for 
up to 8 days.    
Assessment of heart rate recovery 
Heart rate recovery (beats/min) was determined by subtracting the heart rate at one, three 
and five minutes after exercise from the maximum heart rate achieved at 20 m/min speed at the 
end of the exercise period. These were designated as HRR1, HRR3, and HRR5 (e.g., HRR1 = 
beats/min at 0 minutes after exercise – beats/min at 1 min after exercise). Heart rate recovery data 
were collected on days 0 (pre-treatment), 7, 14 and 28 after initiating PYR administration. 
Acetylcholinesterase and butyrylcholinesterase activity  
Blood samples were collected on days 0, 7, 14 and 28 for determining blood 
cholinesterase (ChE) activities. An aliquot of whole blood was collected, and plasma and red 
blood cells (RBCs) were separated by centrifugation (5000 x g, 2 min).  The RBCs were washed 
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by resuspension in phosphate buffered saline solution, centrifuged as before and the supernatant 
was discarded. The washing step was repeated three times. Plasma and washed RBCs were then 
stored at -80°C until analysis. Acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and 
total ChE activity were measured in the plasma, whereas only AChE activity was measured in 
RBCs, using a radiometric method with [
3
H] acetylcholine iodide (1 mM final concentration) as 
the substrate and incubation at 26°C [7]. To determine total cholinesterase activity, plasma 
samples with no selective inhibitor were assayed in the enzyme reaction. To estimate BChE 
activity, the specific acetylcholinesterase inhibitor BW284c51 (1, 5-
bis[allyldimethylammoniumphenyl] pentane-3-dibromide, 2 µM, Sigma-Aldrich (St. Louis, MO, 
USA) was added 1 minute prior to adding substrate. AChE activity was defined as the difference 
in acetylcholine hydrolysis between total ChE and BChE. Preliminary assays were carried out to 
determine incubation times that resulted in linear rates of substrate hydrolysis from 30 sec to 30 
min incubation.  
To determine the in vitro sensitivity of cholinesterases to PYR, blood was collected from 
a different set of three naïve rats, and plasma and RBCs were separated as before and stored at -
80°C. To determine the in vitro sensitivity of plasma BChE to pyridostigmine, all reactions 
contained 284c51 (2 µM) and either vehicle (50 mM potassium phosphate buffer, pH 7) or one of 
a range of concentrations of pyridostigmine (0.0003 to 30 µM) in the vehicle. To determine in 
vitro sensitivity of plasma AChE to pyridostigmine, all samples contained the 
butyrylcholinesterase-selective inhibitor ethopropazine (Sigma-Aldrich) (10 µM dissolved in 50 
mM potassium phosphate buffer, pH 7 containing 1% ethanol and either vehicle or one of a range 
of concentrations of pyridostigmine. In all cases, reactions were pre-incubated at 26°C for 30 
minutes before adding substrate and measuring residual activity.  
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Pharmacological determination of autonomic tone 
The autonomic tone was assessed in freely moving, conscious rats. On day 27, basal heart 
rate (HRbasal) was recorded for 10 minutes. Atropine sulfate (Henry Schein, Dublin, Ohio, USA) 
was injected intraperitoneally, at a dose rate of 2 mg/kg [8-10] to block parasympathetic input to 
the heart. The HR recorded 15 min after atropine injection was defined as HRatropine, i.e., HR 
primarily under the influence of the sympathetic and the intrinsic cardiac nervous systems. 
Propranolol (4 mg/kg, IP, West-Ward Pharmaceutical Corp., Eatontown, NJ, USA) was then 
administered and HR was again recorded 15 min later and defined as HRintrinsic, i.e., HR with both 
parasympathetic and sympathetic innervation blocked. The sympathetic tone was estimated using 
HRatropine and HRintrinsic as below in equation 1.   
Equation 1: 
𝑆𝑦𝑚𝑝𝑎𝑡ℎ𝑒𝑡𝑖𝑐 𝑡𝑜𝑛𝑒 =  
𝐻𝑅𝑎𝑡𝑟𝑜𝑝𝑖𝑛𝑒 − 𝐻𝑅𝑖𝑛𝑡𝑟𝑖𝑛𝑠𝑖𝑐
𝐻𝑅𝑖𝑛𝑡𝑟𝑖𝑛𝑠𝑖𝑐
∗ 100 
Where, HRatropine = HRsympathetic + HRintrinsic 
Similarly, on day 29, after recording HRbasal for 10 min, propranolol was administered as 
described above [8-10]. HR recorded 15 min after propranolol injection was termed the 
HRpropranolol, under the influence of the parasympathetic and intrinsic cardiac nervous systems. 
Atropine was administered at a dose rate of 2 mg/kg and the HR was recorded after 15 min of 
injection for determination of HRintrinsic. The parasympathetic tone was calculated using 
HRpropranolol and HRintrinsic as shown below in equation 2. 
Equation 2: 
𝑃𝑎𝑟𝑎𝑠𝑦𝑚𝑝𝑎𝑡ℎ𝑒𝑡𝑖𝑐 𝑡𝑜𝑛𝑒 =  
𝐻𝑅𝑝𝑟𝑜𝑝𝑟𝑎𝑛𝑜𝑙𝑜𝑙 −  𝐻𝑅𝑖𝑛𝑡𝑟𝑖𝑛𝑠𝑖𝑐
𝐻𝑅𝑖𝑛𝑡𝑟𝑖𝑛𝑠𝑖𝑐
∗ 100 
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Where, HRpropranolol = HRparasymapathetic + HRintrinsic 
Statistical analysis 
All data are presented as the mean ± SEM. Comparison of the basal HR and maximum 
HR were performed using two-way repeated measures ANOVA followed by Dunnett’s test for 
multiple comparisons. Similarly, HRR and ChE enzyme activity were analyzed using repeated 
measures two-way ANOVA followed by Sidak’s (to compare between treatment groups) and 
Dunnett’s (to compare day 7, 14 and 28 with day 0) test for multiple comparisons. For 
measurements that were obtained only once (i.e., sympathetic tone, parasympathetic tone, 
intrinsic HR, weight gain, and water intake), a student’s t-test was used to assess differences. The 
level of significance was set at α < 0.05. In vitro inhibition data were fitted to a nonlinear curve to 
calculate the IC50 by using nonlinear curve fitting of the inhibitor dose-response function in 
GraphPad Prism 6® (GraphPad Software, Inc., La Jolla, CA). 
Results 
Pyridostigmine intake and in vivo and in-vitro inhibition of cholinesterase activity  
Pyridostigmine in tap water was stable in the dark at both room temperature and 4° C for 
up to 8 days. During the experimental period, water bottles containing either fresh water or water 
containing freshly-prepared pyridostigmine solution were replaced after every three days. There 
were no significant differences in body weight gain (CTL, 55 ± 4 g; PYR, 51 ± 4 g, P=0.53)) or 
water consumption (CTL, 100 ± 5 ml/kg/day; PYR, 106 ± 6 mL/kg/day, P=0.47).Pyridostigmine 
intake was estimated at 15 ± 1 mg/kg/day in the PYR group.  
Rat blood plasma contains relatively similar levels of both AChE and BChE while rat 
RBCs contain primarily only AChE [11]. Fig. 1A shows that total ChE activity in plasma was 
decreased by 32%, 43% and 36% in the PYR group relative to controls on days 7, 14 and 28, 
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respectively  (P<0.001 for interaction term). Fig. 1B shows the effects of PYR on plasma AChE 
activity, which was reduced by 57%, 80%, and 66% of control on days 7, 14 and 28, respectively 
(P<0.001 for interaction term). In contrast, there was no significant reduction in plasma BChE 
activity following PYR exposure at any time-point seen in Fig. 1C. Similar to reductions in 
plasma AChE, AChE activity in RBCs was also markedly lower (64%, 66%, and 66%, Fig. 1D) 
on days 7, 14, and 28 following PYR administration (P<0.001 for interaction term). When 
compared to day 0, all the aforementioned enzyme activities were significantly lower on all 
subsequent days in the PYR group (P<0.001 for total ChE, plasma AChE, and RBC AChE, and 
P<0.01 for plasma BChE). These in vivo data suggested that AChE was more sensitive to 
inhibition by PYR than BChE. 
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Figure 1: Cholinesterase activity in CTL and PYR rats. The total plasma cholinesterase (A), 
plasma acetylcholinesterase (B) and plasma butyrylcholinesterase (C) and red blood cell 
acetylcholinesterase activity (D) were analyzed on days 0, 7, 14 and 28 of pyridostigmine 
administration. Data are presented as the mean ± SEM. *P<0.05 compared to CTL group, 
†P<0.05 compared with day 0. 
 
We also evaluated in vitro sensitivity of AChE and BChE to inhibition by PYR. Figure 2 
shows that the IC50 (95% confidence interval) for PYR was relatively similar against AChE in 
both RBC (0.1020 µM; 0.088 - 0.119) and plasma (0.1775 µM; 0.139 - 0.227). In contrast, BChE 
in plasma was markedly (more than an order of magnitude) less sensitive to in vitro inhibition by 
PYR, with a mean IC50 of 2.272 µM (2.071 - 2.493). 
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Figure 2: In vitro inhibition of red blood cell AChE, plasma AChE and BChE activity by 
pyridostigmine. Tissues were pre-incubated with pyridostigmine for 30 minutes at 26°C prior to 
adding substrate and measuring residual activity. Enzyme activity was expressed as mean percent 
of control activity in the absence of inhibitor. 
 
Heart rate recovery 
As shown in Table 1 and Fig. 3A, basal HR was similar between groups (P=0.325). 
However, Table 2 and Fig. 3B shows that the maximum or peak HR at the maximum running 
speed of 20 m/min was significantly lower in PYR rats as compared to pretreatment values on 
days 7, 14 and 28 (P=<0.001, for days term).  
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Table 1: Effect of pyridostigmine on the basal heart rate of rats on day 0, 7, 14, and 28 of 
pyridostigmine administration.  
Day 
Basal HR of CTL 
(beats/min) 
Basal HR of PYR 
(beats/min) 
0 366±13 363±20 
7 374±16 344±17 
14 388±18 350±19 
28 342±13 329±9 
 
Data are presented as the mean±SEM. HR=heart rate, CTL=control group, PYR=pyridostigmine 
treated group. 
Table 2: Maximum heart rate of rats at 20 m/min running speed recorded during exercise on day 
0, 7, 14, and 28 of pyridostigmine administration. Data are presented as the mean±SEM. 
HR=heart rate, CTL=control group, PYR=pyridostigmine treated group.* P<0.05 compared with 
day 0. 
Day 
Max HR of CTL 
(beats/min) 
Max HR of PYR 
(beats/min) 
0 546±13 540±13 
7 531±15 518±13
*
 
14 530±11 518±14
*
 
28 530±11 500±16
*
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Figure 3: Basal and maximum heart rate. The basal heart rate (A) before exercise and maximum 
heart rate (B) at the maximum running speed of 20 m/min was measured on days 0, 7, 14 and 28 
during pyridostigmine administration. Data are presented as the mean ± SEM. †P<0.05 compared 
with day 0. 
 
Pyridostigmine administration increased HRR as compared with CTL rats, at 1, 3 and 5 
minutes after the end of the exercise, i.e., HRR1, HRR3 and HRR5 (Table 3 and Figs. 4A, B, and 
C respectively). The HRR1 in PYR rats was significantly higher than in the CTL group on days 7, 
14 and 28 (P=0.002 for interaction term, Fig. 4A). The HRR3 was significantly higher in PYR 
rats on day 7, but not on day 14 or 28 (P=0.015 for interaction term, Fig. 4B). Similarly, HRR5 
was significantly higher on days 7 but not on day 14 and 28 (P = 0.036 and 0.019 for days and 
treatment term, Fig. 4C).  
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Table 3: Heart rate recovery of rats recorded before the treatment on day 0 and days 7, 14, and 28 
during the pyridostigmine administration. Data are presented as the mean±SEM. HR: heart rate, 
HRR: heart rate recovery, CTL: control group, PYR: Pyridostigmine group. *P<0.05 compared to 
CTL group, †P<0.05 compared with day 0. 
Days CTL 
(beats/min) 
PYR 
(beats/min) 
 HRR1 
0 117±9 112.3±8 
7 98.3±7 142±10
*†
 
14 82±10
†
 136±14
*
 
28 102±10 132.3±6
*
 
 HRR3 
0 160.3±14 147±8 
7 117±3
†
 158.3±9
*
 
14 130±13 157±12 
28 124±15
†
 128±5 
 HRR5 
0 159.3±10 162±7 
7 134±10 171±8
*
 
14 127±10
†
 162±13
*
 
28 123.1±10
†
 150.3±8 
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Figure 4: Heart rate recovery after exercise. The 1, 3 and 5 min (A, B, and C) HRR was 
measured on days 0, 7, 14 and 28 during pyridostigmine administration. Data are presented as the 
mean ± SEM. *P < 0.05 compared to CTL group, †P<0.05 compared with day 0. 
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Autonomic tone and intrinsic heart rate 
Fig. 5 shows that parasympathetic tone was increased in the PYR rats as compared to the 
CTL group, as indicated by a greater bradycardic response (3% vs 17% decrease in HR, P<0.001) 
after propranolol administration. In contrast, there was no difference in sympathetic tone (28% vs. 
29% increase in HR, P=0.99) between the treatment groups after atropine administration. Intrinsic 
HR was 374 ± 9 vs. 368 ± 8 beats/min (P=0.4) and 349 ± 10 vs. 352 ± 11 beats/min (P=0.53) in 
CTL and PYR groups on days 27 and 29, respectively (data not shown).  Basal HR was also 
similar between the groups on day 27 (338 ± 12 and 324 ± 10 beats/min in CTL and PYR groups, 
respectively, P=0.4); however, on day 29, basal HR was significantly lower in the PYR group 
(350 ± 7 vs. 321 ± 9 beats/min in CTL and PYR groups, respectively P=0.02; data not shown). 
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Figure 5: Modulation of autonomic tone represented by the alteration in heart rate following 
pharmacological intervention in PYR and CTL groups. The HR response associated with atropine 
sulfate administration is represented by the negative change in HR, whereas the bradycardic 
response caused by propranolol administration is represented by a positive change in HR. Data 
are presented as the mean ± SEM. *P<0.05 compared to CTL group. 
 
Discussion 
Heart rate recovery is measured as the reduction in heart rate at specified times after 
moderate to heavy exercise. In other words, it is the rate at which the heart decelerates after 
moderate to heavy exercise and is dependent on the dynamic relationship between 
parasympathetic and sympathetic innervation [12] of the cardiac tissues. During and after 
exercise, parasympathetic and sympathetic control of the heart adjusts according to metabolic 
demands. Savin and colleagues [2] studied cardiac function in normal patients with and without 
selective autonomic blockers and proposed that sympathetic withdrawal contributes more to the 
decrease in heart rate soon after exercise, while the parasympathetic system is predominant later 
in the recovery phase. However, recent studies have proposed that parasympathetic reactivation 
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occurs faster than sympathetic withdrawal in heart rate recovery, thus playing a major role in the 
early deceleration of the heart [13-17]. Our study was designed to explore the relative 
contributions of the sympathetic and parasympathetic systems on heart rate recovery following 
forced running exercise in rats.   
Barnard and coworkers reported relatively few differences in HRR among different ages 
of rats exercised until exhaustion [18]. To the best of our knowledge, there is no other published 
literature on HRR in rats for comparison.  To develop an exercise model in rats to study HRR and 
the cardiac neuroendocrine system, we modified an exercise protocol from a previous study by 
Copp and coworkers [3]. Using this exercise model, we determined that subacute administration 
of pyridostigmine in rats enhanced heart rate recovery (Fig. 4). Pyridostigmine can modify 
parasympathetic control of cardiac function by blocking the enzymatic breakdown of 
acetylcholine at vagal nerve terminals. This can lead to enhanced activation of muscarinic 
receptors regulating cardiac muscle contraction.  A single dose of pyridostigmine in CHF patients 
led to an increase in heart rate recovery recorded 1 min after exercise [19]. In 2007, Dewland et 
al. showed that in sedentary adults, pyridostigmine decreased resting heart and increased post-
exercise heart rate recovery at 1 min, but had no significant effect on trained athletes [20]. The 
study by Dewland and colleagues explained post-exercise heart rate recovery as an index of 
cholinergic signaling in the sinoatrial nodal junction. Serra et al. reported that repeated 
pyridostigmine dosing increased HRR and other hemodynamic parameters in human CHF 
patients [21]. Our study demonstrated the augmented effect of subacute pyridostigmine treatment 
(28 days in the drinking water) on heart rate recovery in rats (Fig. 4).The results from our study 
thus generally agree with and model those reported previously in humans. However, in this study, 
basal heart rate did not differ significantly between treatment groups (Fig. 3), contrasting with 
results obtained from a study performed in rats with induced heart failure rats [22]. This 
discrepancy may be due to physiological differences between normal rats used in the current 
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study as compared to those with heart failure. In heart failure rats, a positive chronotropic 
condition occurs as a consequence of the withdrawal of the parasympathetic system [22]. The 
indirect parasympathomimetic drug, pyridostigmine, enhances cardiac vagal tone. Thus a greater 
negative chronotropic effect would be expected in the rats with heart failure. A smaller drug 
effect would, therefore, occur with pyridostigmine administration to normal rats. This smaller 
magnitude effect, along with day to day variability, may also explain why mean basal HR was 
lower in PYR rats as compared to CTL rats before exercise and on day 27 before pharmacological 
estimation of autonomic tone, but was only significantly lower on day 29 before pharmacological 
estimations.  
Soares et al. reported that 0.14 mg/mL pyridostigmine in the drinking water of rats 
resulted in an average pyridostigmine intake of 31 mg/kg/day [5]. These investigators reported 
that this concentration of pyridostigmine led to approximately 40% inhibition of plasma 
acetylcholinesterase activity after a seven day treatment period [5]. Although the average 
pyridostigmine intake in our study was estimated to be only 15 mg/kg/day, AChE inhibition after 
seven days of drug administration was 57% and 64% in rat plasma and RBCs, respectively (Fig. 
1). Other studies used the same pyridostigmine dosing conditions in rats as Soares et al. and the 
resulting intake of the drug was also higher compared to our estimate of intake [4, 6, 22, 23]. The 
relatively lower intake of pyridostigmine by our rats may be attributed to evidence of higher 
water intake by young rats used in the above-listed studies as compared to the older rats used in 
our study [24].   
Moreover, when compared to 30% cholinesterases inhibition by pyridostigmine in HRR 
studies performed in human subjects, the level of inhibition of acetylcholinesterases was 
generally higher in our study (Fig. 1). This may contribute to the substantial enhancement of 
HRR noted in our study (Fig. 4).    
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We noted substantial differences in the level of AChE and BChE inhibition following in 
vivo PYR exposure (Fig. 1). We, therefore, evaluated the relative in vitro sensitivity of AChE and 
BChE to inhibition by pyridostigmine. In both the RBC and plasma, pyridostigmine was a more 
potent in vitro inhibitor of AChE compared to BChE, confirming that pyridostigmine has a higher 
inhibitory effect on AChE than BChE (Fig. 2). The lower IC50 of AChE compared to BChE 
agrees with the lesser BChE inhibition noted in our in vivo studies. A previous report indicated 
that in vitro measurements of human and rat AChE may also show differences in sensitivity 
towards pyridostigmine [25]. The slight difference in in vitro sensitivity of AChE in plasma vs. 
AChE in RBCs noted in our study may be due to differences in PYR detoxification in the plasma 
vs. RBC fractions. Pyridostigmine is a carbamate acetylcholinesterase enzyme inhibitor, and 
some carbamate anticholinesterases are metabolized by plasma carboxylesterases [26]. Thus, 
there may be more stoichiometric binding sites for pyridostigmine in the plasma vs. the RBC 
fraction, and thus less inhibition of AChE in plasma with similar concentrations of 
pyridostigmine. Pyridostigmine may also bind to plasma albumin [27], decreasing its relative in 
vitro inhibition of the enzyme in plasma.  
In the present study, subacute administration of pyridostigmine increased 
parasympathetic tone but had no apparent effect on sympathetic tone (Fig. 5). In contrast, in a 
previous study on heart failure in rats, both parasympathetic and sympathetic tones were 
decreased by pyridostigmine administration [22]. However, in both heart failure rats from this 
previous study and in the normal rats used in our current study, intrinsic heart rate did not differ 
between the PYR and CTL groups. According to Lataro et al., in rats with heart failure, 
improvement of cardiac sympathetic tone could be due to effects of pyridostigmine on 
cholinergic transmission in the sinoatrial node [22]. Pharmacological blockade of the sympathetic 
and parasympathetic nervous systems by the administration of selective blocking agents are 
useful for assessing autonomic tone [15, 28-30]. Lataro et al. subtracted HRbasal from HRatropine to 
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estimate parasympathetic tone, and then subtracted that value from HRpropranolol to estimate 
sympathetic tone [22]. However, after subtracting the basal HR from the HRatropine or HRpropranolol, 
the intrinsic HR still influences HR and confounds the interpretation of relative effects of the 
autonomic system. We proposed that changes in autonomic tone could be better evaluated by 
subtracting the intrinsic HR from HRatropine to get sympathetic tone, and then subtracting that 
value from HRpropranolol to estimate parasympathetic tone (Equations 1 and 2). This approach may 
exclude the influence of intrinsic activity while individually isolating the parasympathetic and 
sympathetic contributions. 
Conclusion 
The data support our hypothesis that subacute PYR dosing enhances HRR by increasing 
cardiac parasympathetic tone in rats. Post-exercise HRR can be used to assess autonomic tone 
and thus can serve as an indicator of cardiovascular fitness. The present model of HRR after 
submaximal exercise should be suitable for future studies in rats with heart failure. 
  
 65 
 
References 
1. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992;340(8811):88-92. 
2. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in 
patients with heart disease. The New England journal of medicine. 1971;285(16):877-83. 
3. Kinugawa T, Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left 
ventricular dysfunction and heart failure. The American journal of physiology. 1995;268(2 Pt 
2):R310-16. 
4. Malliani A, Pagani M. Spectral analysis of cardiovascular variabilities in the assessment of 
sympathetic cardiac regulation in heart failure. Pharmacological research. 1991;24 Suppl 
1:43-53. 
5. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, et al. Power spectral 
analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal 
interaction in man and conscious dog. Circulation research. 1986;59(2):178-93. 
6. Laterza MC, de Matos LD, Trombetta IC, Braga AM, Roveda F, Alves MJ, et al. Exercise 
training restores baroreflex sensitivity in never-treated hypertensive patients. Hypertension. 
2007;49(6):1298-306. 
7. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in 
cardiovascular disease: physiological basis and prognostic implications. Journal of the 
American College of Cardiology. 2008;51(18):1725-33. 
8. Heart rate variability: standards of measurement, physiological interpretation and clinical use. 
Task Force of the European Society of Cardiology and the North American Society of Pacing 
and Electrophysiology. Circulation. 1996;93(5):1043-65. 
 66 
 
9. Imai K, Sato H, Hori M, Kusuoka H, Ozaki H, Yokoyama H, et al. Vagally mediated heart 
rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart 
failure. Journal of the American College of Cardiology. 1994;24(6):1529-35. 
10. Perini R, Orizio C, Comande A, Castellano M, Beschi M, Veicsteinas A. Plasma 
norepinephrine and heart rate dynamics during recovery from submaximal exercise in man. 
European journal of applied physiology and occupational physiology. 1989;58(8):879-83. 
11. Buchheit M, Papelier Y, Laursen PB, Ahmaidi S. Noninvasive assessment of cardiac 
parasympathetic function: postexercise heart rate recovery or heart rate variability? American 
journal of physiology Heart and circulatory physiology. 2007;293(1):H8-10. 
12. Yilmaz A, Erdem A, Kucukdurmaz Z, Karapinar H, Gul I, Sarikaya S, et al. Abnormal heart 
rate recovery in stable heart failure patients. Pacing and clinical electrophysiology : PACE. 
2013;36(5):591-5. 
13. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery 
immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of 
mortality: the case of stress echocardiography. Circulation. 2001;104(16):1911-6. 
14. Uchechukwu D. Post-Exercise Heart Rate Recovery: An index of cardiovascular fitness. J 
Exe Physiol. 2009;12(1). 
15. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and 
treadmill exercise score as predictors of mortality in patients referred for exercise ECG. Jama. 
2000;284(11):1392-8. 
16. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery 
immediately after exercise as a predictor of mortality. The New England journal of medicine. 
1999;341(18):1351-7. 
 67 
 
17. Pierpont GL, Voth EJ. Assessing autonomic function by analysis of heart rate recovery from 
exercise in healthy subjects. The American journal of cardiology. 2004;94(1):64-8. 
18. Pierpont GL, Stolpman DR, Gornick CC. Heart rate recovery post-exercise as an index of 
parasympathetic activity. Journal of the autonomic nervous system. 2000;80(3):169-74. 
19. Shetler K, Marcus R, Froelicher VF, Vora S, Kalisetti D, Prakash M, et al. Heart rate 
recovery: validation and methodologic issues. Journal of the American College of 
Cardiology. 2001;38(7):1980-7. 
20. Barnard RJ, Duncan HW, Thorstensson AT. Heart rate responses of young and old rats to 
various levels of exercise. J Appl Physiol. 1974;36(4):472-4. 
21. Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. Acetylcholinesterase 
inhibition with pyridostigmine improves heart rate recovery after maximal exercise in 
patients with chronic heart failure. Heart. 2003;89(8):854-8. 
22. Serra SM, Costa RV, Teixeira De Castro RR, Xavier SS, Nobrega AC. Cholinergic 
stimulation improves autonomic and hemodynamic profile during dynamic exercise in 
patients with heart failure. Journal of cardiac failure. 2009;15(2):124-9. 
23. Wilson BW, Henderson JD. Blood esterase determinations as markers of exposure. Rev 
Environ Contam Toxicol. 1992;128:55-69. 
24. Borresen J, Lambert MI. Autonomic control of heart rate during and after exercise : 
measurements and implications for monitoring training status. Sports medicine. 
2008;38(8):633-46. 
 68 
 
25. Savin WM, Davidson DM, Haskell WL. Autonomic contribution to heart rate recovery from 
exercise in humans. Journal of applied physiology: respiratory, environmental and exercise 
physiology. 1982;53(6):1572-5. 
26. Javorka M, Zila I, Balharek T, Javorka K. Heart rate recovery after exercise: relations to heart 
rate variability and complexity. Brazilian journal of medical and biological research = Revista 
brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica  [et al]. 
2002;35(8):991-1000. 
27. Kannankeril PJ, Goldberger JJ. Parasympathetic effects on cardiac electrophysiology during 
exercise and recovery. American journal of physiology Heart and circulatory physiology. 
2002;282(6):H2091-8. 
28. Kannankeril PJ, Le FK, Kadish AH, Goldberger JJ. Parasympathetic effects on heart rate 
recovery after exercise. Journal of investigative medicine : the official publication of the 
American Federation for Clinical Research. 2004;52(6):394-401. 
29. Copp SW, Davis RT, Poole DC, Musch TI. Reproducibility of endurance capacity and 
VO2peak in male Sprague-Dawley rats. Journal of applied physiology. 2009;106(4):1072-8. 
30. Dewland TA, Androne AS, Lee FA, Lampert RJ, Katz SD. Effect of acetylcholinesterase 
inhibition with pyridostigmine on cardiac parasympathetic function in sedentary adults and 
trained athletes. American journal of physiology Heart and circulatory physiology. 
2007;293(1):H86-92. 
31. Lataro RM, Silva CA, Fazan R, Jr., Rossi MA, Prado CM, Godinho RO, et al. Increase in 
parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of 
heart failure. American journal of physiology Regulatory, integrative and comparative 
physiology. 2013;305(8):R908-16. 
 69 
 
32. Soares PP, da Nobrega AC, Ushizima MR, Irigoyen MC. Cholinergic stimulation with 
pyridostigmine increases heart rate variability and baroreflex sensitivity in rats. Autonomic 
neuroscience : basic & clinical. 2004;113(1-2):24-31. 
33. de La Fuente RN, Rodrigues B, Moraes-Silva IC, Souza LE, Sirvente R, Mostarda C, et al. 
Cholinergic stimulation with pyridostigmine improves autonomic function in infarcted rats. 
Clinical and experimental pharmacology & physiology. 2013;40(9):610-6. 
34. Sabino JP, da Silva CA, de Melo RF, Fazan R, Jr., Salgado HC. The treatment with 
pyridostigmine improves the cardiocirculatory function in rats with chronic heart failure. 
Autonomic neuroscience : basic & clinical. 2013;173(1-2):58-64. 
35. Sabino JP, da Silva CA, Giusti H, Glass ML, Salgado HC, Fazan R, Jr. Parasympathetic 
activation by pyridostigmine on chemoreflex sensitivity in heart-failure rats. Autonomic 
neuroscience : basic & clinical. 2013;179(1-2):43-8. 
36. Thunhorst RL, Beltz T, Johnson AK. Age-related declines in thirst and salt appetite responses 
in male Fischer 344xBrown Norway rats. Physiology & behavior. 2014;135:180-8. 
37. Lorke DE, Hasan MY, Nurulain SM, Shafiullah M, Kuca K, Petroianu GA. Pretreatment for 
acute exposure to diisopropylfluorophosphate: in vivo efficacy of various 
acetylcholinesterase inhibitors. Journal of applied toxicology : JAT. 2011;31(6):515-23. 
38. Gupta RC, Dettbarn WD. Role of carboxylesterases in the prevention and potentiation of N-
methylcarbamate toxicity. Chemico-biological interactions. 1993;87(1-3):295-303. 
39. Abu-Qare AW, Abou-Donia MB. Binding of pyridostigmine bromide, N,N-diethyl-m-
toluamide and permethrin, alone and in combinations, to human serum albumin. Archives of 
toxicology. 2002;76(4):203-8. 
 70 
 
40. Jose AD, Taylor RR. Autonomic blockade by propranolol and atropine to study intrinsic 
myocardial function in man. The Journal of clinical investigation. 1969;48(11):2019-31. 
41. Polanczyk CA, Rohde LE, Moraes RS, Ferlin EL, Leite C, Ribeiro JP. Sympathetic nervous 
system representation in time and frequency domain indices of heart rate variability. 
European journal of applied physiology and occupational physiology. 1998;79(1):69-73. 
42. Smith ML, Hudson DL, Graitzer HM, Raven PB. Exercise training bradycardia: the role of 
autonomic balance. Medicine and science in sports and exercise. 1989;21(1):40-4. 
43. Johnson CD, Russell RL. A rapid, simple radiometric assay for cholinesterase, suitable for 
multiple determinations. Analytical biochemistry. 1975;64(1):229-38. 
44. Kuwahara M, Yayou K, Ishii K, Hashimoto S, Tsubone H, Sugano S. Power spectral analysis 
of heart rate variability as a new method for assessing autonomic activity in the rat. Journal of 
electrocardiology. 1994;27(4):333-7. 
45. Sanyal SN, Ono K. Derangement of autonomic nerve control in rat with right ventricular 
failure. Pathophysiology : the official journal of the International Society for Pathophysiology 
/ ISP. 2002;8(3):197-203. 
46. Chapleau MW, Sabharwal R. Methods of assessing vagus nerve activity and reflexes. Heart 
failure reviews. 2011;16(2):109-27.
 71 
 
CHAPTER IV 
 
 
USE OF HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY–TANDEM MASS 
SPECTROMETRY FOR THE QUANTIFICATION OF PYRIDOSTIGMINE AND ITS 
METABOLITE, 3 HYDROXY N-METHYLPYRIDINIUM IN HUMAN PLASMA 
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Abstract 
Analytical methods were developed to quantify pyridostigmine (PYR) and its metabolite 
3-hyroxy-N-methylpyridinium (3-OH NMP) in human plasma using a sensitive liquid 
chromatography–electrospray ionization–tandem mass spectrometry assay. For PYR sample 
preparation, plasma was processed by a solid phase extraction procedure, using weak cation 
exchange (WCX) cartridges and 3-OH NMP was precipitated by acetonitrile. Hydrophilic 
interaction liquid chromatography separation was performed with a Restek® Ultra PFPP (3µm, 
150 X 4.6mm) column. The mobile phase consisted of 30% of 50 mM ammonium formate (pH 
3.25) and 70% of 1:1 acetonitrile:methanol for PYR and 2mM ammonium formate in 1% formic 
acid solution in water and methanol for 3-OH NMP. Two calibration curves were utilized for 
PYR to achieve linearity over the range of concentrations, low and a high calibration curves 
spanned over 0.25–10 ng/mL and 5–100 ng/mL, respectively. The calibration curve for 3-OH 
NMP ranged from 1 to 200 ng/mL. The intra and inter-day accuracy of PYR were above 95%, 
and coefficient of variation was at or below 15%. Similarly, intra and inter-day accuracy of 3-OH 
NMP were above 95%, and coefficient of variation was at or below 9%. The lower limit of 
quantitation (LLOQ) of PYR and 3-OH NMP assays was determined to be 0.25 and 1 ng/mL, 
respectively. At the LLOQ, intra-day accuracy was above 80%, and coefficient of variation was 
below 14% for PYR and 94% and below 10% respectively for 3-OH NMP.  The average recovery 
of PYR from plasma was 93%, 97% and 86% at 0.8, 8 and 80 ng/mL, respectively. The average 
recovery for the internal standard, neostigmine was similar to that of PYR at 92%.  
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Introduction 
Pyridostigmine (PYR) is a positively charged quaternary ammonium carbamate 
compound, which binds to the acetylcholinesterase (AChE) enzyme on a negatively charged site 
and an esteric site. Thus PYR prevents acetylcholine (ACh) from binding to these same sites and 
being broken down by the enzyme. This inhibition leads to the buildup of ACh, which is not 
being hydrolyzed, resulting in an increased action of ACh on its receptor. Pyridostigmine inhibits 
acetylcholinesterase enzyme for a longer duration of time than neostigmine (1). Pyridostigmine 
bromide was first approved by the FDA in 1955 to treat a neuromuscular disease, myasthenia 
gravis. The FDA has given pyridostigmine “orphan drug” status. FDA designates orphan drug 
status to drugs and biological products which are intended for use in treatment, diagnosis or 
prevention of rare diseases. Pyridostigmine is the first drug to be approved under the “animal 
efficacy rule of FDA”, in Feb 2003 as a prophylactic agent at 30 mg dose taken three times a day. 
Use of PYR in military personnel was intended to increase survival after exposure to Soman 
nerve gas poisoning (2).  
Pyridostigmine is being studied for its beneficial cardiovascular effects during heart 
failure. Recent studies suggest that pyridostigmine attenuates the development of hypertension 
and inflammation in spontaneously hypertensive rats (3). Pyridostigmine also improves the 
cardio-circulatory function in rats with chronic heart failure (4) and prevents ventricular 
dysfunction during the onset of the heart failure in rats (5). In human congestive heart failure 
patients, a 45 mg pyridostigmine tablet administered orally three times a day resulted in improved 
post-exercise hemodynamic profile such as inhibition of chronotropic response, enhancement of 
heart rate reserve and heart rate recovery at 1 min after the exercise (6).  
There are several published methods for the identification and quantification of 
pyridostigmine from biological fluids using gas chromatography-mass spectrometry (GC/MS) (1, 
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7), enzymatic or immunoassay methods (8, 9), HPLC methods (10-12) and a thermospray LC/MS 
method (13). These methods are less selective, rapid or sensitive. As compared to liquid 
chromatography, due to the derivatization steps, the time required for sample processing is longer 
in gas chromatography. Moreover, the enzymatic methods are not as selective in distinguishing 
between drugs and the metabolites which resemble chemically in biological fluids. Additionally, 
HPLC methods followed by UV or fluorescence detectors have long analysis time (run time) and 
may require ion-pairing agents in the mobile phase to obtain proper peak shape and for the 
retention on the C8 and C18 stationary phases (14). These ion-pairing agents may interact with 
the analytes of interest and interfere in quantification. A mass spectrometry method with the low 
runtime, high selectivity, and enhanced sensitivity is required to address these limitations. In this 
study, we report two separate tandem mass spectrometry methods for the determination of 
pyridostigmine and its metabolite, 3-hydroxy-N-methylpyridinium, in human plasma. This 
method was applied for the quantification of these analytes in the plasma collected from human 
congestive heart failure patients.  
Materials and methods 
Chemicals and reagents 
Pyridostigmine bromide (Pyridinium, 3-[[(dimethylamino)carbonyl]oxy]-1-methyl-, 
bromide; 99.8% purity) (PYR) was obtained from U.S. Pharmacopeial Convention (USP, 
Rockville, MD USA). 3-hydroxy-N-methylpyridinium bromide (3-OH NMP) was obtained from 
TLC PharmaChem Inc. (Vaughan, Ontario, Canada). The internal standards, Neostigmine 
bromide (NEO) (≥98% purity) for PYR method and Eserine (ESE) (≥98% purity) for the 3-OH 
NMP method, were obtained from Sigma-Aldrich (St. Louis, MO USA). Standard stock solutions 
were prepared 1% formic acid in methanol solution. HPLC grade ammonium formate, formic 
acid, citric acid, sodium phosphate, methanol, and other reagents were purchased from Fisher 
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Scientific Company (New Jersey, NJ). Oasis® WCX 3mL solid phase extraction cartridges were 
purchased from Waters ® Corporation, (Milford, MA).  
Instrumentation 
An Applied Biosystems 4000 Q-Trap MS/MS system (Applied Biosystems, Foster City, 
CA) and a NitroGen N300DR nitrogen generator (Peak Scientific Instruments Ltd., Paisley, 
United Kingdom) were used with an electrospray ionization source for the fragmentation and 
detection of the analytes. A Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan) was 
used to separate the analyte for detection and quantification. This liquid chromatography system 
consisted of a system controller (CBM-20A), binary solvent delivery unit (LC-20AD), in-line 
degasser (DGU-20A5), an auto-sampler (SIL-20AC) with thermostatic injector set at 4 °C and a 
column oven set at 40 °C (CTO-20AC). The separation column used was a Restek® Ultra PFPP 
(3µm, 150 X 4.6mm) column (Restek, Bellefonte, PA). Data was acquired and analyzed by the 
Multiquant and Analyst® 1.5 software. For the measurement of both PYR and 3-OH NMP, 25 
µL were injected, and the auto-sampler was set at 4°C temperature. 
Data was collected in a Multiple reaction monitoring (MRM) mode. Based on collision-
induced dissociation (CID) product ion scan spectra, MRM transitions ions were selected for 
detection of analytes. The method was run under positive ion mode. The values of curtain gas 
pressure (CUR), ion spray voltage (IS), temperature (TEM), pressure of ion source gas 1 (GS1), 
ion source gas 2 (GS2), declustering potential (DP), entrance potential (EP), collision energy 
(CE) and collision cell exit potential (CXP) for both methods are shown in Table 1.  
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Table 1: Optimal mass spectrometry instrument parameter settings for pyridostigmine and 3-OH 
NMP methods.  
Parameters Value for Pyridostigmine 
assay 
Value for 3-OH NMP 
assay 
CUR 20 20 
IS 1000 1000 
TEM 700 550 
GS1 40 80 
GS2 30 60 
DP 40 40 
EP 5 5 
CE (eV) 20 20 
CXP 10 10 
 
Abbreviations: Curtain gas pressure (CUR), ion spray voltage (IS), temperature (TEM) , pressure 
of ion source gas 1 (GS1), ion source gas 2 (GS2), declustering potential (DP), entrance potential 
(EP), collision energy (CE) and collision cell exit potential (CXP) 
a. Mobile phase 
The mobile phase for the PYR method consisted of 30% of 50 mM ammonium formate 
(pH 3.25) and 70% of 1:1 acetonitrile: methanol. Mobile phase for 3-OH NMP method consisted 
of 2mM ammonium formate in 1% formic acid solution in water and methanol. Isocratic elution 
achieved separation at a flow rate of 0.5 mL/min. 
b. Standard solutions 
Stock solutions of PYR and 3-OH NMP were made in 1% formic acid in methanol 
solutions. Then the stock solutions were diluted make the working solutions in mobile phase B. 
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The working solutions were used to fortify pooled unmedicated human plasma (Innovative 
Research®, Novi, MI) to get the final concentrations of 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, 75, and 
100 ng/mL for PYR and 1, 2.5, 5, 10, 25, 50, 100, and 200 for 3-OH NMP standard curves. 
Working solutions of 10ug/mL NEO and ESE were prepared similarly.  
c. Sample preparation 
Different separation techniques were employed for PYR and 3-OH NMP. After thawing, 
the pooled human plasma was fortified by PYR or 3-OH NMP separately at different 
concentrations to get a total volume of 500 uL of fortified plasma as required for calibration 
curves and quality control samples. For sample preparation of PYR, 500 uL of fortified plasma or 
patients’ plasma sample were diluted with 500 uL of 50 mM citrate phosphate (CP) buffer, 
pH=5.8, containing 50 ng/mL of NEO. Solid phase extraction technique was used to separate 
PYR through weak cation exchange (WCX) cartridges from Oasis®. The cartridges were 
conditioned with 2mL of methanol and CP buffer and then the diluted sample was loaded as 
passed slowly through using a positive pressure manifold. The cartridge was then rinsed with one 
mL of CP buffer followed by one mL methanol and dried under maximum pressure for ten mins. 
Lastly, the retained analytes were eluted with 20% formic acid solution of pH 2 in 80% methanol 
and collected in glass tubes. The samples were then dried under a gentle nitrogen gas stream for 
30 min at 35°C. Samples were reconstituted with 100 µL of a mixture of 30% mobile phase A 
and 70% mobile phase B solution and transferred to injection vials. 
Five hundred uL of fortified human plasma or a patient plasma sample was precipitated 
with one mL of acetonitrile containing 25 ng/mL of the internal standard ESE to clean the 
samples for 3-OH NMP. The tubes were then centrifuged for 10 min at 4000 g speed. One mL of 
supernatant was transferred to a new glass tube and dried under nitrogen gas in the Turbovap for 
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30 min at 35°C. Samples were reconstituted with 100 µL of a mixture of 50% mobile phase A 
and 50% mobile phase B solution.  
d. Calibration curves 
For the quantification of pyridostigmine and 3-OH NMP, the ratio of peak area of the 
analyte to the peak area of the respective internal standards was used. For PYR, the calibration 
curve split into low and high curves, with the high curve ranging from 0.25 to 10 ng/mL and the 
low curve from 5 to 100 ng/mL, to obtain acceptable linearity. For quantification of 3-OH NMP, 
a single calibration curve ranging from 1 to 200ng/mL was used. To plot a calibration curve, at 
least six calibrators were included. In the analysis of PYR, 1/y
2
 weighting was used for high and 
low calibration curves whereas, for 3-OH NMP curve, weighting was not required.  At the lower 
limit of quantitation, the acceptable limit of accuracy was set to 20% of nominal concentrations 
and coefficient of variation within 20%. Acceptability criteria for all runs included accuracy 
within 15% of at least five retained calibrants and an R
2
 of 0.99 or above. Quality control (QC) 
samples of three different concentrations (0.8, 8 and 80 ng/mL for PYR and 8, 40 and 160 ng/mL 
for 3-OH NMP) in six replicates were also included in the validation experiments.  
e. Method Validation 
Method was evaluated by determining the intraday and interday accuracy and CV% of 
the six replicates of the of the quality control samples. Coefficient variation (CV), or standard 
deviation divided by the mean predicted concentration was expressed as a percentage, and this 
represented the precision of the method. The accuracy of within 20% of the nominal 
concentration at the lower limit of quantitation (LLOQ) and 15% of the nominal concentration at 
all (at least five out of six) higher concentrations was set as the acceptable limits. Similarly, a CV 
of less than 20% at the LLOQ and less than 15% at higher concentrations were set as the 
acceptable parameters for a successful run.  
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In mass spectrometry methods, plasma components that are extracted with the analytes 
may alter the signal response, causing either ion suppression or enhancement. This may result in 
poor analytical accuracy and linearity. Thus, matrix effects were determined in the method by 
preparing samples in triplicates at nominal concentrations of 0.8, 8 and 80 ng/mL of 
pyridostigmine in plasma. Peak areas of analytes in resuspending buffer were defined as A; 
analytes fortified before extraction as B and analytes fortified after extraction from plasma as C.   
The determination of the matrix effect, recovery efficiency and process efficiency were 
determined by the following formulae: 
Matrix effect (%) = C/A × 100 
Recovery efficiency (%) = B/C × 100 
Process efficiency (%) = B/A × 100 
f. Specificity 
Samples were assayed along with internal standard and in the presence of metabolites and 
drugs in the plasma. It was important to determine the effect of the presence of an internal 
standard, metabolite (in case if pyridostigmine method) and drug (in the case of 3-OH NMP 
method) on the quantification. Thus to assess this effect, the peak areas of the quality control 
samples of each analyte were compared with and without the present of other analytes.  
g. Stability 
To determine the stability of the analytes during storage (-80°C), test were performed on 
samples of the drug and the metabolite. A reversed-phase high-performance liquid 
chromatography method was originally developed with a maximum sensitivity of 10ng/mL. This 
method was used to test the stability of PYR and 3-OH NMP in the 1% formic acid in methanol 
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solution. This solution was used to prepare the stock and working solutions to store until use and 
thus it was necessary to test the stability of the drug in this solution. 
h. Application to human pharmacokinetic study of pyridostigmine and its metabolite in 
congestive heart failure patients 
This novel highly sensitive analytical method was altered to address the issues of 
impaired specificity and then successfully applied to quantify the concentrations of 
pyridostigmine and 3-OH NMP in plasma collected from16 adult CHF patients involved in a 
clinical trial at New York University. These patients orally self-administered pyridostigmine 
initially at 15 mg every 8 hours for two weeks with subsequent planned uptitration to 30 mg 
every 8 hours for two weeks, and 60 mg every 8 hours for four weeks. The dosing regimen then 
followed a downtitration to 30 and 15 mg every 8 hours for one week each. Plasma samples were 
collected at different times across the study period.  
Results and Discussion 
Sample pretreatment optimization 
Several different sample processing methods were investigated to optimize sample 
recovery and chromatography. Previously published solid phase extraction (SPE) by Octadecyl 
(C18)-bonded silica has been the most widely employed SPE adsorbent in the cartridge for both 
PYR and 3-OH NMP (17, 18). Abu-Qare et al. used the C18 SEP-PAK cartridge and reported 
recovery rates of 77% for PYR and 79% for 3-OH NMP, whereas Ellin et al. (19) claimed 
recovery rates of >90% for PYR with similar SPE material. Other previously reported SPE 
cartridges, such as HLB (20), C8 Bond Elute (12), Bond Elut C2 (21), and CBA (22), were also 
tested for recovery. In our experimental settings with human plasma, the recoveries of PYR with 
HLB, CBA, and WCX cartridges were promising (Figure 2). However, the recovery of the 
internal standard NEO was lower with HLB as compared to PYR, and there was interference in 
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chromatography which may be due to insufficient cleaning of the samples when CBA cartridges 
were used. Hence, WCX cartridges were ultimately used to extract PYR and NEO from human 
plasma with approximately 90% recovery as shown in Table 2. 
Figure 1: Recovery of Pyridostigmine and Neostigmine through different SPE cartridges 
 
 
Table 2: Mean percentages of matrix effects, recovery efficiency, and process efficiency of 
extraction of plasma samples fortified with pyridostigmine and neostigmine in triplicate; fortified 
at the concentrations of 0.8, 8 and 80 ng/mL pyridostigmine and 100 ng/mL neostigmine.  
 
PYR conc 
(ng/mL) 
Matrix  
Effect (%) 
Recovery 
Efficiency (%) 
Process  
Efficiency (%) 
0.8 17 93 78 
8 2 97 99 
80 4 86 89 
NEO 100 5 92 97 
 
To extract 3-OH NMP from human plasma, HLB, Trace B, Trace N and MCX cartridges 
were tested.  Trace N and HLB columns had poor recoveries, whereas Trace B and MCX 
columns did not remove the interfering substance. Hence, a protein precipitation method was 
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successfully employed. Protein in the plasma samples was precipitated with acetonitrile, and the 
supernatant was collected for drying. The sensitivity of 3-OH NMP method was poorer than that 
of the PYR method because more drug was lost during protein precipitation and sample 
preparation whereas, most of the drug is recovered in the SPE method.  
Chromatographic optimization 
Few obstacles made the analyses of PYR and 3-OH NMP difficult. Low molecular 
weights of PB (181.21) and 3-OH NMP (79.9) predispose interference from other small 
molecules present in biological matrices (23, 24). The molecule is highly polar, and thus it is 
difficult to obtain ideal chromatographic results in terms of peak shape and retention on the 
typical hydrophobic stationary columns such as C8 or C18 (25).  
In previous studies, columns used for the determination of PYR and its metabolites are 
almost exclusively reverse-phase (RP) (10, 11, 14, 17, 19, 26-28). These RP columns ranged from 
150 to 300 mm in length and 3.2 to 4.6 mm in internal diameter. The particle size in these 
columns was either 5 or 10 µm. Needham et al. compared previous reversed-phase methods to 
their LC/MS/MS method for the analysis of PYR in guinea pig plasma using SCX columns and 
reported five folds lower LLOQ (25). We explored the RP-18, Atlantis HILIC, and Restek Ultra 
PFPP columns. Restek Ultra PFPP column using hydrophilic interaction chromatography 
(HILIC) method for separation gave the best results for our analytes. Polar compounds are 
retained well in HILIC through preferential partitioning between a more hydrophobic mobile 
phase and an immobilized liquid layer enriched in water (29, 30). Pyridostigmine and its 
metabolite 3-OH NMP are highly polar in nature, and so the HILIC method of separation allowed 
the analytes to retain at the stationary phase.  
Different mobile phases were also tried to improve the separation of analytes. Isocratic 
elution with 30% of 50 mM ammonium formate (pH 3.25) and 70% of 1:1 acetonitrile:methanol 
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for PYR and 2mM ammonium formate in 1% formic acid solution in water and methanol for 3-
OH NMP at a flow rate of 0.5 mL/min efficiently resulted in pertinent separation and Gaussian 
peak shape of the analytes. Resuspending buffer was injected after every highest calibration run, 
and it was found that there are no subsequent carryovers of the analytes from the previous runs.  
Mass Spectrometry Instrument setting and optimization 
Analytes were dissolved in methanol and directly injected to determine the optimal 
instrument settings. The mass spectrometry setting such as curtain gas pressure (CUR), ion spray 
voltage (IS), temperature (TEM) , pressure of ion source gas 1 (GS1), ion source gas 2 (GS2), 
declustering potential (DP), entrance potential (EP), collision energy (CE) and collision cell exit 
potential (CXP) were optimized. The aim of the optimization was to remove or decrease 
interfering molecules, increase the sensitivity of the method and gain optimum separation of the 
analytes.   We also compared the chromatograms in ESI vs. APCI mode and found that there was 
more background noise in APCI mode, and it had low sensitivity. To overcome these problems, 
ESI with positive mode ionization was used to get satisfactory sensitivity.  
Multiple reaction monitoring (MRM) in which a typical fragment ion is selected amongst 
several ions from the complex matrix and quantified was used in this method (31).  MRM plots 
are very simple, usually containing only a single peak.  These characteristics make the MRM plot 
ideal for sensitive and specific quantitation (31). 
Specificity 
The identification (ID) ratios of qualifier ions for each analyte was determined to assess 
that specificity of the method. Based on FDA guidelines for method development ID ratios within 
±20% of mean of ID ratios were considered as acceptable (32). The mass to charge ratios (m/z) of 
precursor ions were 180.7, 223.3, 109.98, and 276.1 for pyridostigmine, neostigmine, 3-OH 
NMP, and eserine, respectively. For quantitation of analytes, major transitions were chosen, such 
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as 180.7/72.95, 223.3/151.0, 109.98/66.9 and 276.1/219 for pyridostigmine, neostigmine, 3-OH 
NMP, and eserine, respectively. For identification of analytes, qualifier transitions were 
180.7/125.1, 223.3/208.9, 109.98/38.9 and 276.1/94.4 for pyridostigmine, neostigmine, 3-OH 
NMP, and eserine respectively. Figure 3 and 4 shows chromatograms of PYR and NEO and 3-
OH NMP and ESE respectively. 
Figure 2: Representative chromatogram of fortified human plasma with 100ng/mL 
pyridostigmine (PYR) and 100 ng/mL neostigmine (NEO, internal standard). 
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Figure 3: Representative chromatogram of fortified human plasma with 100ng/mL N-methyl 
pyridinium bromide (3-OH NMP) and 25 ng/mL eserine (ESE, internal standard).  
 
Stability 
Both PYR and 3-OH NMP, at 10 and 100 ng/mL, were stable in 1% formic acid in 
methanol and mobile phase solution for up to 30 days. The potency of 10 and 100 ng/mL PYR 
samples over a 30 day period remained > 98% and the coefficient of variation < 3%. Similarly, 
the potency of 10 and 100 ng/mL 3-OH NMP samples over a 30 day period was maintained at > 
95%, and CV was <5%.  
Calibration curve 
A wide range of pyridostigmine calibrants was included (0.25–100 ng/mL) in plasma to 
quantify the expected concentrations of pyridostigmine in human plasma. Peak areas of PYR 
were not linear over the range of anticipated plasma concentrations, so the calibration curve was 
split into two, 0.25–10 ng/mL and 5–100 ng/mL for the low and a high calibration curves, 
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respectively (16). Both of the curves were linear across the range with an R2 value of >0.997. A 
1/(concentration)2 weighting scheme was applied to both low and high curves. The 3-OH NMP 
curve was linear across the 1 to 200ng/mL range, and the R
2
 value of >0.999 was obtained 
without weighting. The PYR calibration curve reported in a previously published method for 
guinea pig plasma samples was narrow and ranged from 0.1 to 50 ng/mL (25). The calibration 
curves reported in this paper were broad to cover the expected higher plasma concentrations of 
pyridostigmine in human samples.  
Method validation 
Matrix effects, recovery efficiency, and processing efficiency were each calculated for 
pyridostigmine and neostigmine in plasma (15). Table 2 shows that recovery at all QC 
concentrations of PYR was higher in this reported method as compared to a previously published 
method by Needham et al. in Guinea pig plasma (25). The higher recovery could be attributed to 
the use of an SPE method for sample preparation as compared to the liquid-liquid extraction 
method reported by Needham et al. (25). In the current method for developed for PYR, the intra-
day accuracy for pyridostigmine was above 97%, and coefficient of variation (CV) was at or 
below 5%, whereas, the inter-day accuracy was 95% and CV was below 15% respectively (Table 
3 and 4). The lowest value of the intraday and inter-day accuracy was 95%, indicating a good 
accuracy of the developed method. The LLOQ of pyridostigmine was 0.25ng/mL with an 
accuracy and CV of 80.2 and 13.3%, respectively (Table 4). For 3-OH NMP, the calibration 
curve ranged from 1 to 200 ng/mL, and the LLOQ was one ng/mL with an accuracy and CV of 94 
and 9.5% respectively (Table 4). The intra-day accuracy for 3-OH NMP was above 96%, and 
coefficient of variation (CV) was at or below 9%, whereas the inter-day accuracy was 95% and 
CV was below 9%, respectively (Table 3 and 4).  
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Table 3: Intra-day accuracy and precision of analytes in plasma were presented as a mean ± 
standard deviation. The intraday accuracy and precision of both analytes were within acceptable 
limits. 
Analyte Intra-day precision and accuracy (n=6) 
 Nominal conc. 
(ng/mL) 
Observed conc. (ng/mL) 
(mean ± SD)  
CV (%) Accuracy 
(%) 
PYR 0.8 0.8±0.04 5 98.6 
 8 7.8±0.13 1.7 97.8 
 80 77.8±1.5 1.9 97.2 
3-OH NMP 8 8.3±0.3 4 96.7 
 40 40.7±2.9 7 98 
 160 160.3±13.7 8.6 99.8 
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Table 4: The values of inter-day accuracy and precision of analytes in plasma in eight runs of 
PYR and three runs of 3-OH NMP were presented as a mean ± standard deviation. The values of 
inter-day accuracy and precision of both analytes were within acceptable limits. 
Analyte Inter-day precision and accuracy (n=6) 
 Nominal conc. 
(ng/mL) 
Observed conc. (ng/mL) 
(mean ± SD)  
CV (%) Accuracy 
(%) 
PYR 0.8 0.8±0.13 15 95 
 8 7.8±0.24 3.2 97.2 
 80 79.1±1.7 2.1 98.9 
 0.25 (LLOQ) 0.23±0.03 13.3 80.2 
3-OH NMP 8 7.7±0.4 5.5 97.2 
 40 41.7±0.97 2.3 95.5 
 160  160.3±13.7 8.6 99.8 
 1 (LLOQ) 1.06±0.1 9.5 94 
 
Application to pyridostigmine in human plasma samples 
The PYR and 3-OH NMP concentrations determined in human plasma ranged from 1.15 
to 88.09ng/mL and from 1.07 to162 ng/mL, respectively. Figure 5 represents a pharmacokinetic 
profile of pyridostigmine and its metabolite, 3-OH NMP, in a human congestive heart failure 
patient. As seen in figure 5, the assays were adequately able to describe the plasma disposition of 
orally administered pyridostigmine in this human CHF patient. However, the observed plasma 
concentrations of the metabolite 3-OH NMP were higher than the plasma concentrations of PYR 
at all time points. Previous studies indicate that orally administered pyridostigmine undergoes 
high first pass metabolism, which reduces the fraction of unchanged drug eliminated in urine, and 
the fraction of the metabolite is increased as compared with intravenous administration (33). 
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Therefore, enterohepatic recycling of the metabolite may be another possible reason for the 
increased metabolite concentration in plasma as compared to the parent drug.  
It is also possible that during storage and thawing steps, pyridostigmine underwent 
hydrolysis by the cholinesterases enzymes present in the plasma leading to higher concentrations 
of NMP in plasma. However, this contradicts with the previous findings where pyridostigmine 
was slowly metabolized and so the metabolite concentrations in urine and liver did not exceed 
more than 25% of the excreted radioactivity (34). A freeze-thaw stability of pyridostigmine and 
metabolite in plasma would be helpful in determining the effect of storage and thawing on the 
analytes. It is also possible that the analytical method developed for NMP produced erroneous 
results, since this assay was subsequently found to be difficult to replicate due to the presence of 
contaminants that co-eluted with NMP. Given that interfering substances were detected in 
subsequent attempts to use theses assays to quantify both PYR and NMP in plasma, further 
modification and validation of these assays will be required before they can be applied to patient 
samples.    
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Figure 4: A representative time course disposition of pyridostigmine bromide (PYR) and 3-
hydroxy N-methyl pyridinium bromide (3-OH NMP) in a human congestive heart failure patient 
(104.3 kg body weight), that received oral doses of 15, 30 and 60 mg (initially escalating and then 
descending) tablets three times a day.  
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Conclusion 
In conclusion, a sensitive and selective method was validated for the routine LC/MS/MS 
analysis of PYR and 3-OH NMP from human plasma. The method used WCX columns to retain 
PYR and separate the analytes from the plasma, whereas a protein precipitation method was 
employed to separate 3-OH NMP from plasma. The HILIC mode of LC separation was used, and 
eluted drugs were quantified via MRM positive ion mode ESI in a tandem mass spectrometer. 
The method, with modifications to improve specificity, was applied to a population 
pharmacokinetic and study of pyridostigmine bromide in congestive heart failure patients.  
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CHAPTER V 
 
 
POPULATION PHARMACOKINETIC ANALYSIS OF PYRIDOSTIGMINE IN 
CONGESTIVE HEART FAILURE PATIENTS 
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Abstract 
This study was conducted to characterize the population pharmacokinetics of 
pyridostigmine given as pyridostigmine bromide. For eight weeks, 16 congestive heart failure 
patients received oral escalating doses of 15, 30 and 60 mg pyridostigmine bromide every eight 
hours. Plasma concentrations of pyridostigmine were determined at various times within visit 1 to 
12 conducted on days -14, -7, 0, 7, 14, 21, 28, 42, 56, 63, 70 and 77 with a ±4 day window.  One 
and two compartment models with first-order absorption and elimination was fitted to the 
resulting pharmacokinetic data. Nonlinear mixed effects modeling was performed using 
NONMEM, interfaced with PDx- Pop. Model-to-data fitting was performed using the first-order 
conditional estimation (FOCE) method with interaction. The performance of each model was 
evaluated by computing the objective function values (OFV), Akaike Information Criterion 
(AIC), Schwarz Bayesian criterion (SIC) and diagnostic plots. As a result, in a one-compartment 
model, the typical values for CL/F, Vd/F, and Ka were 187 ± 14.6 L/h, 101 ± 16 L and 0.06 ± 
0.004/h, respectively. The inter-individual variability for CL/F, Vd/F, and Ka was 29.0%, 1.39%, 
and 21.3%, respectively and residual variability was 52.4% for the model. The terminal half-life 
(t½) was 0.37 h. However, in a two compartment model, typical values for CL/F, Vd/F, Q/F, 
Vss/F and Ka were, 208 L/h, 1110 L, 509 L/h, 9290 L, and 0.748 L/h, respectively. The 
interindividual variability in CL/F, Vd/F, Q/F, Vss/F and Ka was 31.4%, 36.5%, 25.9%, 35.6% 
and 5.32% respectively and residual variability was 46.7% for the model. The terminal phase 
half-life (t½) was 3.7 h.  In conclusion, a two compartment model showed a lower OFV, AIC, 
and SIC and had better diagnostic plots suggesting a better representation of the data. 
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Introduction 
Heart failure is a complex clinical syndrome that suggests impairment of the heart as a 
pump supporting physiological circulation. Heart failure is caused by structural or functional 
abnormalities of the heart (1).  Abnormalities in neuroendocrine regulation are considered to be 
an important determinant of disease progression in patients with chronic heart failure (2, 3). 
Abnormal cardiac autonomic control, characterized by sympathetic activation and 
parasympathetic withdrawal, is one of the major manifestations of neuroendocrine dysregulation 
in heart failure (4). Pharmacological inhibition of sympathetic activation by the systemic 
administration of adrenergic receptor blockers has been shown to improve survival in clinical 
trials (5). Therefore, traditional heart failure therapy mainly includes β-blockers, angiotensin 
converting enzyme (ACE) inhibitors, positive inotropic agents and aldosterone antagonists (5).  
In recent studies, attention has focused on the management of heart failure with the 
administration of parasympathetic system activators, such as pyridostigmine. Pyridostigmine is an 
acetylcholinesterase inhibitor, which activates the parasympathetic system by reversibly binding 
to acetylcholinesterase enzyme (6-8). Studies suggest that pyridostigmine administration benefits 
rats with heart failure during its progression by reducing sympathetic tone and decreasing cardiac 
remodeling and attenuating left ventricular dysfunction (9). Pyridostigmine also reduced 
baroreflex sensitivity, power in the low-frequency (LF) band of the systolic atrial pressure 
spectrum, cardiac parasympathetic tone, and intrinsic HR (10) which had beneficial effects on 
heart failure rats. In human subjects, repeated pyridostigmine administration increased heart rate 
recovery (HRR) and had beneficial effects on other hemodynamic parameters in human CHF 
patients (11, 12).  
Initially, pyridostigmine bromide was indicated for the symptomatic treatment of 
myasthenia gravis, a chronic muscle disease, by the US Food and Drug Administration (FDA) in 
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1955. Later, pyridostigmine bromide was approved by the FDA for use during the 1990–1991 
Gulf War as a prophylactic agent against nerve gas poisoning by Soman (13). 
However, very limited human data is available for the pharmacokinetic and 
pharmacodynamic of pyridostigmine bromide (14-20). Available studies were performed on 
small subject sizes or did not incorporate all the important covariates in the model. Two 
population pharmacokinetic and pharmacodynamic (PKPD) studies were previously reported for 
pyridostigmine bromide (21, 22). In the first study by Marino et al., the data were obtained from 
Caucasian subjects, and this analysis incorporated only demographic covariate information during 
model development (22). In the second population PKPD study by Seng et al., relevant dosing 
regimens were identified for Chinese subjects and other potential covariate relationships were 
determined (21). However, both the population PKPD studies were conducted with regards to 
nerve agent exposure. Hence, our population pharmacokinetic study was designed to characterize 
the pharmacokinetic parameters of pyridostigmine and identify the variability of these parameters 
in a population of patients with heart failure.   
The overall aim of this population analysis was to develop a model characterizing the 
steady state pharmacokinetics of repeated oral administration of pyridostigmine bromide in 
patients with congestive heart failure. Also, in this study, we tested the hypothesis that population 
pharmacokinetic modeling will determine the variability in the dose-response amongst the CHF 
patient population and estimate pharmacokinetic parameters of pyridostigmine in patients with 
CHF. 
Material and methods 
Study design, study population and pyridostigmine regimen 
A prospective, randomized, double-blind, parallel group, forced titration, ascending dose 
study was designed. Thirty-three eligible subjects with chronic heart failure associated with left 
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ventricular systolic dysfunction were enrolled in the study. All participants were provided written 
consent and necessary HIPAA authorization in accord with institutional and Federal guidelines. 
Eligible subjects were selected from the heart failure population at NYU Langone Medical 
Center. Inclusion criteria; age 21-75 years, symptomatic NYHA Class II-III heart failure >6 
months, left ventricular ejection fraction <35%, etc. and exclusion criteria; e.g. contraindications 
to cholinergic stimulation, sick sinus syndrome, resting heart rate <60 or >100 min-1, pregnant or 
breastfeeding women, etc., were used to determine the eligibility of the subjects to participate in 
the study. Various demographics such as race, ethnicity, age and gender, as well as clinical and 
laboratory parameters of liver and renal function, etc. were documented during each study visit 
for all of the subjects (Table 1). Creatinine clearance (CLCR) was calculated according to 
Schwartz’s formula (23). Glomerular filtration rate (GFR) was calculated by the Cockcroft-Gault 
formula (24).  
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Table 1: Variables for the study population in the pyridostigmine pharmacokinetic analysis 
Characteristics Units Mean ± SD 
(n=16) 
Range 
Hemoglobin g/dL 13.11 ± 1.33 6.5 to 15.5 
Sodium mmol/L 139.35 ± 2.36 132 to 147 
Serum Creatinine mg/dL 1.11 ± 0.34 0.6 to 2.2 
Glomerular filtration rate  mL/min 92.02 ± 23.86 42.29 to 169.95 
Alanine Aminotransferase  units/L 28.56 ± 11.17 10 to 59 
Aspartate aminotransferase  units/L 27.66 ± 8.49 14 to 61 
Weight kg 82.27 ± 16.81 51.6 to 116.6 
Height cm 166.91 ± 6.28 156 to 176 
Age years 54.31 ± 9.58 27 to 70 
Gender N/A N/A 14 Male, 16 Female 
Race N/A N/A 9 White, 4 Black, 3 Asian 
Ethnicity N/A N/A 8 Hispanic, 8 non-Hispanic 
NYHA Functional 
Classification 
N/A N/A 14 Class II, 2 Class III 
 
The study drug, pyridostigmine bromide was self-administered by the subjects at 
approximately 8-hour intervals. The study drug was initiated at 15 mg every 8 hours for two 
weeks with subsequent planned uptitration to 30 mg every 8 hours for two weeks, and then 
maintained at 60 mg every 8 hours for four weeks. Study drug was then downtitrated to 30 and 15 
mg every 8 hours for one week each (Figure 1). If a subject did not tolerate a dose of study drug 
due to excess cholinergic effects such as, sitting or standing systolic blood pressure <90 mmHg, 
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increase in QTC by >50 msec, cholinergic symptoms score > 16, or increased >8 from placebo 
run-in period, resting HR<50 beats/min, etc. the dose was downward adjusted. 
Figure 1: Study Schematic representing the study design and dosing regimen 
 
 
Profiling of Plasma pyridostigmine and 3 hydroxy N-methylpyridinium, red blood cell 
acetylcholinesterase and plasma butyrylcholinesterase activity levels  
The study was conducted in 4 stages: 1) Screening and randomization (Visits 1-3); 2) 
Study drug uptitration (Visits 4-7); 3) Study drug maintenance and primary endpoint assessment 
(Visits 8-9); and 4) Study drug downtitration (Visits 10-12). Visits 1 to 12 were conducted on 
days -14, -7, 0, 7, 14, 21, 28, 42, 56, 63, 70 and 77 with a ±4 day window. Patients were 
examined and screened, and the first dose of the study drug was administered during visit 3. 
Blood was collected in heparinized tubes at visits 3 to 11. The samples were immediately 
centrifuged at 4°C, and plasma was separated for determination of plasma levels of 
pyridostigmine (PYR) and its major metabolite 3 hydroxy-N-methylpyridinium (3-OH NMP) and 
butyrylcholinesterase (BChE) levels. Erythrocytes were washed in isotonic saline solution and 
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centrifuged to discard the supernatant.  RBC was stored for determination of acetylcholinesterase 
(AChE) activity. In order to obtain representative blood samples over a wide range of times, post-
administration, the timing of the study visits were staggered to occur at 2-4 hours post study drug 
at one visit (visits 4, 6, and 9) and 4-6 hours post–administration at one visit (visits 5, 7, and 8) 
for each dose level of study drug. At these visits, one blood sample was drawn upon arrival, and 
another sample was drawn approximately one hour later. In addition, at visits 3, 5, and 7, blood 
samples were drawn immediately before and at 2 hours after administration of study drug in the 
office. The compliance of study drug administration was recorded at each visit. 
Pharmacokinetic assay 
The analytical method which was developed in the previous chapter to quantify 
pyridostigmine (PYR) in human plasma using a sensitive liquid chromatography–electrospray 
ionization–tandem mass spectrometry assay was modified to address the impaired specificity by 
the OSU Forensic Toxicology and Trace Laboratory at Center for Health Sciences, Tulsa, OK. 
Plasma samples were sonicated for approximately 20 minutes to separate the plasma from the 
proteins and clotting factors that could clog the extraction column. The sonicated plasma samples 
are then centrifuged and the supernatant filtered by syringe filters (Thermo Scientific, Waltham, 
Massachusetts, USA) used for extraction of pyridostigmine by solid phase extraction technique 
using weak cation exchange (WCX) cartridges. Secondly, the pumps were set at a binary gradient 
mode to prevent the elution of the contaminant at the retention time of pyridostigmine and thus 
improved the specificity of the method. The MRM ions for pyridostigmine and neostigmine were 
also re-optimized, and results suggest slight changes in the mass to charge ratios (m/z) of 
precursor ions as 182.2 and 223.2 for pyridostigmine and neostigmine, respectively. For 
quantitation of analytes, major transitions were chosen, such as 182.2/71.7 and 223.2/150.0 for 
pyridostigmine and neostigmine, respectively. For identification of analytes, qualifier transitions 
were 182.2/125.1 and 223.2/56.0 for pyridostigmine and neostigmine, respectively. Hydrophilic 
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interaction liquid chromatography separation was performed with a Restek® Ultra PFPP (3µm, 
150 X 4.6mm) column (Restek Corporation, U.S., Bellefonte, PA). The mobile phase consisted of 
30% of 50 mM ammonium formate (pH 3.25) and 70% of 1:1 acetonitrile: methanol and the 
pumps were set in binary gradient mode. 
Calibration curve for PYR to achieve linearity spanned over 1–50 ng/mL with a quadratic 
fit and 1/x weighting. The intra and inter-day accuracy of PYR were above 95%, and coefficient 
of variation was at or below 15%. The lower limit of quantitation (LLOQ) of PYR assays was 
determined to be 1 ng/mL. At the LLOQ, intra-day accuracy was above 80%, and coefficient of 
variation was below 20%.   
Acetylcholinesterase activity inhibition assay 
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were measured 
in the RBC and plasma, respectively.  A radiometric method was used with [3H]acetylcholine (1 
mM final concentration) as the substrate, with a reaction volume of 100 μL, and incubation at 
26°C (25). Butyrylcholinesterase activity in plasma samples was assayed in 50 mM potassium 
phosphate buffer, pH 7.0, without Triton X-100. AChE activity in RBC was assayed in the 
presence of Triton X-100 (0.1% in 50 mM potassium phosphate buffer, pH 7.0). Either 20 μL of 
plasma or 20 μL washed RBC, and 20 μL of radiolabeled substrate ([3H] acetylcholine iodide) in 
50 mM potassium phosphate buffer, pH 7.0 was added in each case. Preliminary assays were 
carried out with 30 s to 30 min incubation times to determine incubation times that produced 
linear rates of substrate hydrolysis.  
To determine non-enzymatic hydrolysis of the substrate, sample reactions with only 
buffer (no tissue) were included. The radiolabeled substrate was added to the reaction vials at 
staggered (10 seconds) intervals to start the incubation and reactions were terminated by 
staggered addition of 100 μl of ChE “stop” solution. The cholinesterase stop solution was 
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prepared by adding 9.45 grams of chloroacetic acid, 2 grams of sodium hydroxide and 11.6 grams 
of sodium chloride to 100 ml of deionized water. Once the reactions had been stopped, 5 ml of 
organic scintillation cocktail was added to each vial. Organic scintillation cocktail for the 
cholinesterase assay consisted of 0.5% (w/v) 2, 5-diphenyloxazole (PPO), 0.03% (w/v) 1, 4-bis 
[5-phenyl-2-oxazolyl] benzene (POPOP) and 10% (v/v) isoamyl alcohol in toluene. The vials 
were capped and vortexed for 5-10 seconds and were then counted in a Tri-Car 2810 TR 
(PerkinElmer, Waltham, MA).   
Population pharmacokinetic model 
The plasma pyridostigmine concentration and time data were simultaneously fitted using 
the nonlinear regression program NONMEM (NONMEM 7.3.0, ICON Development Solution, 
Hanover, MD), interfaced with PDx- Pop (v5.2, GloboMax LLC, Hanover, MD, USA), in 
conjunction with a GFORTRAN compiler and R (R Foundation for Statistical Computing, 
Vienna, Austria) for statistical computing and graphics. Structural base, i.e. covariate-free, 
models were developed to compare model fitting in one and two compartment models.  The 
pharmacokinetic models were developed under assumptions of first-order absorption and 
elimination (21, 22). This model was implemented using the ADVAN2 and TRANS2 PREDPP 
subroutines for one compartment and ADVAN4 and TRANS3 for a two compartment model. 
ADVAN2 and ADVAN4 are routines in PREDPP's library that implement the kinetic equations 
for the one and two compartment linear models with first-order absorption, respectively. 
TRANS2 is a routine in PREDPP's library which performs a re-parameterization of the basic 
pharmacokinetic (PK) parameters to the internal parameters, elimination constant (K) and 
absorption constant (Ka). Similarly, TRANS3 is a routine in PREDPP's library that performs a re-
parameterization of the basic PK parameters to the internal parameters K, K12, K21 
(intercompartmental elimination constants), and Ka.  
 106 
 
The model was fitted to the data by using the first-order conditional estimation (FOCE) 
method with interaction. The pharmacokinetic parameters that were estimated by the one 
compartment analysis were absorption rate constant (Ka), apparent plasma oral clearance (CL /F) 
and apparent volume of distribution after oral administration (Vd/F).The structural 
pharmacokinetic parameters that were estimated in the two compartment analysis were absorption 
rate constant (Ka), apparent plasma oral clearance (CL/F), intercompartmental clearance (Q), 
apparent volume of distribution in the central compartment after oral administration divided by 
bioavailability (V/F), and the volume of distribution at steady state divided by bioavailability 
(Vss/F). The interindividual variability, or between subject variability (BSV), in pharmacokinetic 
parameters was modeled using exponential error models:  
θi = θ * expo (ηi) 
Where, θij is the ith individual value of the parameter, θ the typical value in the 
population and ηi, is the random effect or interindividual variability. A mean of zero was assumed 
for ηi normally distributed variable with standard deviation ω. The covariance of the parameters 
was studied during the modeling process. Residual variability was described by a standard 
proportional error model.  
Yij = Fij*(1+ε1ij) 
Where, Yij is the observed concentration of ith individual on the jth occasion, Fij is the 
population predicted the concentration of ith individual on the jth occasion and ε1ij is the residual 
error. It was assumed that ε had a mean zero and was normally distributed with standard deviation 
σ.  
The performance of each model was evaluated by computing the objective function 
values (OFV), Akaike Information Criterion (AIC), Schwarz Bayesian criterion (SIC) (26), 
checking standard diagnostic plots of observed concentrations vs. model-predicted 
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concentrations, and plots of conditional weighted residuals vs. population model-predicted 
concentrations, subject identification, etc.  
Results 
Alterations in cholinesterase activities 
Fig. 2 shows that the BChE activity in plasma was not affected when compared between 
the groups, however, it was lower on visits six to nine (P<0.001) when compared with 
pretreatment values. As shown in Fig. 3, AChE activity was progressively decreased with time 
and dosing and then returned to normal during down-titration of the pyridostigmine dose, until it 
was discontinued completed on visit 11 (approximately 70 days after beginning pyridostigmine 
therapy). When compared with the pretreatment value, the AChE activity decreased by 
approximately 10, 20 and 30% on visits 4-8.  The activities of AChE were significantly lower on 
visits six to nine when compared to the pretreatment value (P<0.001) as well as between groups 
(P<0.013).  
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Figure 2: Plasma butyrylcholinesterase activity in congestive heart failure patients were analyzed 
on visit 3 to 12 of pyridostigmine administration. Data are presented as the mean (bars) and SEM 
(error bars). 
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Figure 3: RBC Acetylcholinesterase activity in congestive heart failure patients were analyzed on 
visit 3 to 12 of pyridostigmine administration. Data are presented as the mean (bars) and SEM 
(error bars). 
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Population pharmacokinetic analysis 
In total, 217 plasma pyridostigmine concentration–time points were available from the 
subjects for analysis. Based on the minimal change in the objective function value (OFV) and 
similarity in the goodness of fit plots with and without incorporation of a lag time, it was 
concluded that the data did not support the inclusion of an absorption lag time in the population 
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pharmacokinetic model. Parameter values for the one and two compartment population 
pharmacokinetic model are shown in Table 2.  
Table 2: Parameter estimations of the one and two compartment models for pyridostigmine 
Parameter estimates One compartment Two compartment 
CL/F (l/h) 187 208 
Vd/F (l) 101 1110 
Q/F (l/h) - 509 
Vss/F (l) - 9290 
Ka (1/h) 0.0624 0.748 
Ke (1/h) 1.85 0.19 
Tmax (h) 1.89 2.47 
Half-life (h) 0.37 3.70 
Interindividual variability (%) 
CL/F 29.0 31.4 
Vd/F 1.39 36.5 
Q/F - 25.9 
Vss/F - 35.6 
Ka 21.3 5.32 
Residual variability (%) 
 52.4 46.7 
 
One compartment model: Fig. 4 represents the individual plots showing time vs. observed 
concentrations (DV), population predictions (PRED), and individual predictions (IPRE) for each 
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individual. It was noted that at many time point for most of the individuals the PRED and IPRE 
we overestimated indicating a bad fit of the model.  
Figure 4: Individual plots showing time vs. observed concentrations (DV), population 
predictions (PRED), and individual predictions (IPRE) fitted in a one compartmental PK model.   
 
 
The observed vs population-predicted and individual predicted concentrations are 
presented in Fig. 5 and 6, respectively.  
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Figure 5: Observed concentration (DV) vs. population prediction (PRED) in one compartmental 
PK model 
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Figure 6: Observed concentration (DV) vs. individual prediction (IPRE) in one compartmental 
PK model 
 
Overall the fit was judged to be good. However, in the distributions of weighted residuals 
shown in figures 7 and 8 as a function of sampling time and population-predicted values were 
homogenous indicating a good fit of the model to the data but had a non-significant slight 
negative slope.  
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Figure 7: Weighted residual (WRES) vs. time plot for one compartmental PK model 
 
Figure 8: Weighted residual (WRES) vs. population prediction (PRED) plot for one 
compartmental PK model 
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The OFV, AIC, and SIC values for the models are shown in Table 3. It was seen that all 
the parameter values were lower for the two compartment model than the one compartment. 
Table 3: Comparison OFV, AIC and SIC values of one and two compartment model for 
pyridostigmine 
Parameters One compartment Two compartment 
OFV 1175.4 1120.3 
AIC 1189.4 1142.3 
SIC 1213.1 1179.5 
 
The estimated times for maximum concentration after a dose  (Tmax) was 1.89 h, 
calculated from each subject’s conditional estimates of Ka and K by the standard formula: Tmax = 
ln(Ka/K)/(Ka–K) for a one compartment extravascular administration model (27). Typical values 
for CL/F calculated for the studied population were 187 ± 14.6 l/h. The typical values of Vd/F 
and Ka for all subjects were 101 ± 16 and 0.06 ± 0.004/h, respectively. The inter-individual 
variability about CL/F, Vd/F, and Ka was 29.0%, 1.39%, and 21.3%, respectively. The residual 
variability was 52.4% for the model. The terminal half-life (t½), derived from the expression t½ = 
(0.693* Vd/F)/(CL/F), with individual estimates of CL/F and Vd/F from each patient, for 
pyridostigmine plasma concentrations was 0.37 h (Table 2). 
Two compartment model:  
Fig. 9 represents the individual plots showing time vs. observed concentrations (DV), 
population predictions (PRED), and individual predictions (IPRE) for each individual in a two 
compartment model. When compared to the one compartment model, for most of the individuals 
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the PRED and IPRE values were close to the observed concentrations indicating better fitting of 
the two compartment model.  
Figure 9: Individual plots showing time vs. observed concentration (DV), population prediction (PRED), 
and individual prediction (IPRE) fitted in a two compartmental PK model.   
 
The observed vs. population-predicted and individual predicted concentrations are 
presented in Fig. 10 and 11, respectively.  
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Figure 10: Observed concentrations (DV) vs. population predictions (PRED) in two 
compartmental PK model 
 
Figure 11: Observed concentrations (DV) vs. individual predictions (IPRE) in two 
compartmental PK model 
 
0.00
20.00
40.00
60.00
80.00
100.00
120.00
0.00 20.00 40.00 60.00 80.00 100.00 120.00
D
V
 
PRED 
0.00
20.00
40.00
60.00
80.00
100.00
120.00
0.00 20.00 40.00 60.00 80.00 100.00 120.00
D
V
 
IPRE 
 118 
 
 
Figure 12 and 13 represent the distribution of the weighted residuals as a function of 
sampling time and population-predicted values.  The distribution was homogenous indicating a 
good fit of the model to the data.  
Figure 12: Weighted residual (WRES) vs. time plot for two compartmental PK model 
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Figure 13: Weighted residual (WRES) vs. population prediction (PRED) plot for two 
compartmental PK model 
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The estimated time (Tmax) of maximum plasma pyridostigmine concentrations after oral 
pyridostigmine administration was 2.47 h, calculated by the standard formula Tmax = 
ln(Ka/K)/(Ka– K) for a one-compartment extravascular model. The mean value of CL/F calculated 
for the studied population was 208 L/h. The mean values of Vd/F, Q, Vss and Ka were, 1110 L, 
509 L/h, 9290 L, 0.748, respectively. The interindividual variabilities in CL/F, Vd/F, Q, Vss and 
Ka were 31.4%, 36.5%, 25.9%, 35.6% and 5.32%, respectively. The residual variability was 
46.7% for the model. The terminal phase half-life (t½), determined by the formula, t½ = (0.693* 
Vd/F)/(CL/F) using individual estimates of CL/F and Vd/F, for pyridostigmine plasma 
concentrations, was 3.7 h. The observed vs. population-predicted and individual predicted 
concentrations are presented in Figures 10 and 11. Overall the fit was judged to be good, as the 
distributions of weighted residuals as a function of sampling time, population-predicted values, or 
subject ID were homogenous without a significant slope to the best fit linear regression line of the 
residual values (Figures 12 and 13; Table 2). 
Discussion 
The progressive decrease in the AChE activity corresponds to the drug uptitration from 
visits 4-7 (15 and 30 mg) and drug maintenance (60 mg) from visits 8-9. As expected, during the 
down-titration of the drug, AChE activity gradually increased back to approximate pretreatment 
values during visits 10 to 12. Previous studies in humans reported approximately 10% inhibition 
of the RBC AChE activity after administration of 30 mg tablet three times a day which was true 
for animal studies also (22, 28). The dosing simulations performed by Seng et al. suggested that 
the oral administration of 30 mg every six hours would be required to achieve steady-state trough 
percentage inhibition above the recommended 10% in healthy Chinese males. However, in 
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another study by Marino et al. in the Caucasian population, a similar dose every 8 hours was 
recommended (22). 
To our knowledge, this is the first investigation in which nonlinear mixed effect modeling 
has been applied to investigate oral pyridostigmine pharmacokinetics in human congestive heart 
failure patients. The current study developed a population pharmacokinetic model and estimated 
the associated population pharmacokinetic parameters and their associated variability. One and 
two compartment models were compared in this study. For both models, there were no trends or 
patterns in the goodness-of-fit plots, and other model evaluation criteria were also indicated that 
the models described the data well. 
Although we did not estimate the interoccasion variability, the high interindividual 
variability values estimated in this study suggest a low interoccasion variability. In a previous 
study by Seng et al., the authors did not include the interoccasion variability in the model because 
it was found to be greater than the interindividual variability. In such cases, each individual is 
different from each other individual as well as being different from himself on other occasions. In 
that case, it is reasonable to treat the individuals as different subjects on each unique occasion.  
In this study, the residual variability was similar between one and two compartment 
models but was much higher than that estimated previously (21). Residual variability arises from 
multiple sources, including assay variability, errors in sample time collection, and model 
misspecification. In our case, it is important to note that the time of sample collection was not 
identical for all subjects. A wide window of ±4 days around each visit was designed for the 
convenience of the patients. This may have contributed to the higher values of residual variability 
in our models. Secondly, the quantitation limits of the pyridostigmine assay ranged from 1 to 50 
ng/mL. The concentrations that were higher than 50 ng/mL were extrapolated using a quadratic 
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equation and 1/x weighting scheme. This extrapolation may also have added to the increased 
residual variability in the model. 
Our estimates of oral Cl/F, determined from either compartmental model were 
comparable to that reported in a one-compartmental model study by Marino et al. and supports 
the idea of poor absorption of pyridostigmine from the GIT or high metabolism of the drug due to 
the first pass effect (29). The Ka of the two compartment model estimated in this study was 
compatible with the Ka reported in the two compartment population study by Seng et al. (21). 
However, Ka measured by using the one-compartment model in our study was substantially lower 
than the Ka reported by Marino et al., supporting the inadequacy of the one-compartment model 
in our study (22).  
In our current study, the two-compartment model showed lower values of OFV, AIC and 
SIC (Table 3) as compared with the use of the one-compartment model. The minimum OFV 
determined by parameter estimation during model development is important for comparing 
models and ranking them. Similarly, AIC and SIC values aid in comparing complex models by 
compensating for improvements of fit due to increased model complexity (e.g. increased number 
of compartments) (30). Individual plots illustrate how well the model describes the data for any 
given subject. The individual plots of observed, population predicted, and individual predicted 
concentration plotted against time in fig. 4 showed that for most of the individuals and most time 
points, the PRED and IPRE were overestimated by the one-compartment model, again indicating 
a poor fit of the model.  In contrast, the two compartment model gave a better fit for the 
individual plasma pyridostigmine concentration data and prediction values (Fig. 9). Other 
diagnostic plots, such as observed concentration vs. population and individual predictions (Figure 
5, 6, 10 and 11), did not show as much difference between the compartmental models. Similarly, 
when weighted residuals were plotted against time and population predictions (Figure 7, 8, 12 and 
13), the resulting scatter remained similar for both of the models, without any significant trend. 
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The diagnostic plots give a similar idea of the goodness of the models, but the OFV value and 
parameter estimates indicated that the two-compartment model was a better fit for this data set. 
In our study population, the subjects’ renal functions exceeded the upper limits of the 
normal values and body weight, age and liver functions showed a relatively broad range as 
compared with other covariates (Table 1). These abnormal function values of kidneys and liver 
were expected in congestive heart failure patients. However, studies suggest that GFR has an 
inverse graded association with heart failure severity (31), but biochemical parameters of liver 
function, such as AST and ALT, are moderately elevated to two to three times the upper normal 
reference level (32). It would be interesting to include these covariates in the mixed effect model 
to study their relationships to the parameter estimates and test whether such covariates can 
partially explain the variability in the pharmacokinetic model. In the study by Marino et al. (22), 
body weight and gender were significantly correlated to Vd/F and Cl/F but such relationships 
were not observed in the Chinese population study by Seng et al. (21). This discrepancy between 
the two studies was attributed to the narrow range of covariates present in the study by Seng et al. 
and a wider range of covariates in the study by Marino et al. (21, 22).  
However, to support these study findings it is required to study the relationship of 
covariates with the parameter estimates and variability terms. We also recommended performing 
more efficient analysis by procuring larger sample sizes, extensive sampling after the last dose 
and incorporating a higher number of potentially important covariate information. 
Conclusion 
 The pharmacokinetics of pyridostigmine was described using a nonlinear nixed effect 
model and the effects of pyridostigmine on red blood cell AChE and BChE activities were 
determined. A one-compartment and two-compartment model was successfully fitted to the 
plasma pyridostigmine concentration–time data.  
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CHAPTER VI 
 
 
SUMMARY AND CONCLUSION 
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Neuroendocrine dysregulation is considered to be an important determinant of mortality 
and morbidity in patients with congestive heart failure (1). Sympathetic overactivity and 
parasympathetic withdrawal indicate profound dysregulation of autonomic control. It is possible 
that pharmacological intervention may play a role in decreasing mortality by improving 
sympathovagal balance.  
Pyridostigmine is a cholinergic stimulant that binds to the acetylcholinesterase enzyme 
and inhibits its action on acetylcholine. Studies suggest that pyridostigmine can be effective in 
returning the balance between sympathetic and parasympathetic control of the heart (2-5). As a 
consequence, we hypothesized that pyridostigmine administration to congestive heart failure 
(CHF) patients would restore the balance between the sympathetic and parasympathetic arms of 
the autonomic system, improve heart rate recovery, and enhance the rate of survival associated 
with this disease.     
Determination of the effects of pyridostigmine on heart rate recovery in rats 
Rapid heart rate deceleration within the first minute after maximum exercise is regulated 
primarily by reactivation of the parasympathetic nervous system (6, 7). A blunted decrease in 
heart rate during the first minute after maximal exercise has been associated with an increase in 
the subsequent risk of mortality in subjects with and without cardiovascular disease (8-12). To the 
best of our knowledge, there is no other published literature on the use of heart rate recovery 
(HRR) in rats.  We developed a rodent model of HRR to assess parasympathetic tone. Using HRR 
to assess parasympathetic tone is non-invasive, easy to perform and less technical than heart rate 
variability and other such complex assessment methods. Using this exercise model, we 
determined that subacute administration of pyridostigmine in rats enhanced HRR. The results of 
our study were generally in agreement with current knowledge regarding the effects of 
pyridostigmine on heart rate recovery. Pyridostigmine enhanced heart rate recovery by enhancing 
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the parasympathetic tone of the heart. The model could be used in future studies that can answer 
emerging questions regarding the best use of pyridostigmine in CHF patients. 
Analytical method to quantify pyridostigmine and its metabolite in human plasma 
A sensitive analytical method was developed to quantify pyridostigmine (PYR) and its 
metabolite 3-hyroxy-N-methylpyridinium (3-OH NMP) in human plasma using a sensitive liquid 
chromatography–electrospray ionization–tandem mass spectrometry assay. For PYR sample 
preparation, plasma was processed by a solid phase extraction procedure, using weak cation 
exchange (WCX) cartridges, whereas 3-OH NMP was precipitated by acetonitrile. The HILIC 
mode of LC separation was used, and eluted drugs were quantified via MRM positive ion mode 
ESI in a tandem mass spectrometer. The lower limit of quantitation (LLOQ) of PYR and 3-OH 
NMP assays were determined to be 0.25 and one ng/mL, respectively. To our knowledge, the 3-
OH NMP assay developed in our study was the first method to use mass spectrometry to quantify 
3-OH NMP in human plasma. 
Overall, a sensitive and selective method was validated for the routine LC/MS/MS 
analysis of PYR and 3-OH NMP from human plasma. After incorporating modifications to 
improve specificity, the method was applied to a population pharmacokinetic and study of 
pyridostigmine bromide in congestive heart failure patients. This method has higher sensitivity as 
compared to other methods available to quantify pyridostigmine in human samples. 
Population pharmacokinetic model of pyridostigmine in congestive heart failure  
Pyridostigmine bromide was orally administered to human CHF patients for several 
months, and blood samples were collected during the study period to determine the plasma 
concentrations of pyridostigmine and its metabolite, as well of the activity of blood and plasma 
esterases.  The plasma concentrations of pyridostigmine were analyzed using NONMEM 
software and two structural base models; one and two compartment models were compared using 
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a population-based pharmacokinetic approach. A two-compartment model was best fitted to the 
data obtained from repeated oral dosing of pyridostigmine in these CHF patients. The two 
compartment model showed a lower OFV, AIC, and SIC and had better diagnostic plots than did 
the one-compartment model. The typical values for CL/F, Vd/F, Q/F, Vss/F and Ka for the two 
compartment model were, 208 L/h, 1110 L, 509 L/h, 9290L, and 0.748 L/h, respectively. The 
interindividual variability in CL/F, Vd/F, Q/F, Vss/F and Ka was 31.4%, 36.5%, 25.9%, 35.6% 
and 5.32%, respectively, and residual variability was 46.7% for the model. The terminal phase 
half-life (t½) was 3.7 h for the same model. In the future, this population PK base model will aid 
in the development of a model that can assess associations between pyridostigmine dose, 
efficacy, safety, and patient covariates. 
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